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Developing techniques that allow avoiding open-chest surgery for aortic valve re-
placement has been a field of research for many years. A less invasive approach has 
the potential to replace time-consuming surgery with significant impact on pa-
tients’ physical integrity into a simpler procedure with faster recovery. Further-
more, it would leave the patient without visible scar apart from a minor inguinal 
incision.  
 
What started with Andersen’s successful series of transcatheter aortic valve im-
plantations in seven swine in 19921, has become a standard procedure in humans 
and so far has been performed in >50’000 patients worldwide.  
1.1. Historical overview: From prototype valves to current 
transcatheter aortic valves and delivery systems 
Andersens prototype transcatheter aortic valve consisted of a stent and a porcine 
valve. The stent was made of two folded and sutured stainless steel monofilaments. 
The porcine pig valve was sutured to the metallic stent. This stent-valve was then 
crimped onto an inflatable 12 French balloon catheter (see figure). 
 
Figure 1. The stent was construct-
ed with two 0.55 mm stainless steel
wires folded in 15 loops (a). A
three-leaflet porcine aortic valve
was mounted inside the stent and
fixed to the metal by sutures to
form the stent-valve (b) and (c).
Before implantation the stent-valve
was mounted on a deflated three-
foiled balloon dilatation catheter
(d). The diameter of the collapsed
stent-valve was 12 mm (d) and (e).
Balloon inflation expanded the
stent-valve to an external diameter
of 32 mm (f) and (g). Each of the
three balloons were mounted with
two elastic blocks (indicated by
arrows), to prevent migration of the
stent-valve from the middle of the
balloons. (European Heart Journal
1992;13:704-8) 
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It took 10 years after Andersen’s promising series until Cribier performed the first-
in-human transcatheter aortic valve replacement (TAVR)2, using a valve and deliv-
ery system that looked similar to Andersen’s prototype stent-valve: crimped onto 
an inflatable balloon was the Cribier-Edwards equine valve that could be delivered 
through a 24French delivery system. Using antegrade femoral venous access fol-
lowed by a transseptal puncture and after crossing the left atrium and left ventricle, 
the valve was delivered in a sub-coronary annular aortic position. In a multimorbid, 
inoperable patient, the valve was successfully deployed and was functioning well 
for 17weeks, until the patient passed away for non-cardiac reasons. 
 A breakthrough for broader use of the procedure was the introduction of the 
retrograde transfemoral arterial approach developed by Webb3. However, inability 
of crossing the stenotic and calcified aortic valve with a stent-valve mounted on a 
bulky balloon was a common reason for procedural failure in the early days. Fur-
ther developments of the valve (which was now made out of the more commonly 
available bovine pericardium) and the delivery system (where a nose cone facilitat-
ed native valve crossing and a catheter flex mechanism allowed for easier crossing 
of the aortic arch) led to procedural success in >95% of cases. 
 
Developments and progresses in balloon-expandable valves were paralleled by the 
invention of a self-expandable stent-valve. The first generation self-expandable 
valve (CoreValve) was a bovine pericardial valve, sutured onto a self-expandable 
nitinol stent, delivered via a 25French catheter. The valve is sheathed and posi-
tioned in the aortic annulus. Withdrawal of the sheath leads to expansion and de-
ployment of the valve. Replacing the bovine pericardial valve with thinner porcine 
pericardial tissue allowed reducing the diameter of the delivery system to 
21French. The first larger series of 25 patients treated with the porcine pericardial 
CoreValve was published in 20065. 
 
While research and development of the bovine balloon-expandable valves focussed 
on enabling delivery through smaller sheaths, the research focus of self-expandable 
valves was on improving accuracy of positioning and delivery. 
 Both manufacturers succeeded in overcoming the Achilles heels of their prod-
ucts: The most recent commercially available valve systems of the two companies 
are the Edwards SAPIEN XT bovine pericardial valve delivered via the 16French 
Novaflex system and the porcine Medtronic CoreValve Evolut valve, delivered 
through the 18French delivery system. 
 
Procedural complications occur and lead to temporary setbacks. The nature of the 
complications is different as compared to open-heart surgery (e.g. more vascular 
complications, less major bleddings). Despite these complications, the method es-
tablished worldwide thanks to the convincing technique and steady improvements 
and refinements of the valve and the valve-systems (the different complications 
will be summarized and discussed in detail in the ‘discussion section’, Chapter 3). 
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1.2. From transfemoral to other access routes 
The first patient treated with TAVR suffered severe peripheral arterial disease 
(PAD). This led Dr Cribier to choose a venous, transseptal approach. Although suc-
cessful, the transvenous access was too cumbersome to evolve as a standard ap-
proach for TAVR. While a retrograde transfemoral access proved to be reproducible 
with good results, it was limited to patients without significant PAD. Development 
of smaller delivery catheters and sheaths enabled the cardiologists to treat more 
and more patients with a transfemoral TAVR despite the presence of a certain de-
gree of PAD. 
 Alternatives to a retrograde transfemoral arterial approach were developed for 
patients suffering severe PAD. All of them have in common, that they so far ask for a 
surgical cut-down (with a few exceptions), therefore procedures are typically per-
formed in general anaesthesia and lead to longer postprocedural recovery. 
1.2.1. Transapical 
A left antero-lateral thoracotomy is used to expose the left ventricular apex. Purse-
string sutures are placed at the apex lateral to the left anterior descending artery. 
Needle puncture of the left ventricle is followed by introduction of a stiff guide wire 
to the descending aorta, over which the valve delivery sheath is introduced to the 
ventricle. Feasibility of a transapical TAVR using the balloon-expandable Edwards 
valve was shown in 20066, and subsequent publications proved safety and efficacy 
of the approach7. While the antegrade transapical approach enables a direct access 
to the valve, the procedure is hampered by the need for general anaesthesia and the 
more invasiveness of the procedure. 
 Except for a few centres, the transapical approach is only chosen, if the pres-
ence of severe PAD precludes a transfemoral procedure. Comparison of outcomes 
between transfemoral and transapical procedures showed in most publications 
worse outcome, when a transapical procedure was chosen. The higher risk popula-
tion treated with a transapical procedure might in part explain these differences. 
However, in a risk-score matched comparison, better outcome with transfemoral as 
compared to transapical was found for the high and intermediate risk cohort8. A 
higher inflammatory stimulus when using a transapical approach9 might be one 
reason explaining the difference.  
1.2.2. Subclavian 
In case the axillary (and subclavian) artery is big enough in calibre, a surgical cut-
down to the artery allows for introduction of the delivery system through the left or 
right axillary/subclavian artery. Since until recently, there was no transapical de-
livery system for the CoreValve prosthesis, the subclavian access enjoyed great 
popularity in ‘CoreValve centres’. 
P A R T  1  
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True percutaneous subclavian procedures (without surgical cut-down to the ar-
tery) have been performed, but potential vascular complications without the possi-
bility of manually compressing the artery, bear a certain (unpredictable) risk. 
An early series on subclavian TAVR in 3patients was published in 200910, showing 
feasibility of the method. The following year a series of 54 patients proved safety 
and efficacy of this access route with comparable results to a transfemoral ap-
proach11. In the same line and as an alternative to a subclavian approach, some 
centers successfully used the carotid artery as an access route. 
1.2.3. Transaortic 
The most recent development is the transaortic approach. It is the most direct ap-
proach to the aortic valve and avoids crossing of the left ventricle. The first success-
ful procedure was reported in 2009 using the CoreValve prosthesis12 and one year 
later the same procedure was reproduced using the Edwards valve13. In a patient 
with peripheral vascular disease precluding a transfemoral approach and chest 
deformity precluding a transapical approach, an upper partial sternotomy was 
performed. The ascending aorta was exposed and TAVR successfully performed, 
followed by sheath withdrawal and closure of the ascending aorta by tying purse 
strings sutures. 
1.3. From high-risk to lower risk  
Unlike percutaneous coronary intervention, which was first undertaken in low risk 
patients14, 15, TAVR was performed in high-risk, inoperable patient populations. 
Currently, two randomized landmark trials on TAVR exist (PARTNER A and B)16, 17. 
The first PARTNER trial (PARTNER B) proved superiority of TAVR over medical 
treatment in inoperable patients with a 20% absolute mortality reduction and an 
almost 25% absolute risk reduction for cardiovascular death at one year. Besides, 
the percentage of patients with no or mild symptoms was significantly higher after 
undergoing TAVR as compared to medical treatment (75% vs 42%). Indication for 
TAVR in this patient population is generally accepted, except maybe for the very 
sick patients (e.g. very frail, dialysis patients with severe COPD), where meaningful 
symptomatic recovery after TAVR is doubtful and survival is severely impaired due 
to co-morbidities.  
 The second PARTNER trial (PARTNER A) randomized high-risk patients to 
either surgical aortic valve replacement (SAVR) or TAVR. Since the trial was mainly 
performed in the United States, most centres started their TAVR program only 
within the trial. Despite this disadvantage, TAVR proved to be non-inferior to SAVR 
with regard to survival. The subgroup of patients treated with transfemoral TAVR 
even showed a significantly better 30-day survival as compared to SAVR patients 
(as-treated analysis).  
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Peri-procedural risks differed between the two treatment arms: while TAVR pa-
tients suffered more vascular complications and neurologic events, SAVR patients 
encountered more major bleedings and new-onset atrial fibrillation. 
 
Although the PARTNER trials currently represent the best evidence in the TAVR 
field, they might not accurately reflect current outcomes in TAVR. The PARTNER 
trials were performed using the second generation Edwards device. Newer devices 
and delivery systems improved on accuracy of deployment and a markedly reduced 
sheath size lead to a reduction of vascular access complications18. Increased opera-
tor experience also improves outcomes in TAVR, as previously shown19. Registry 
data therefore probably more accurately reflect current outcomes and practice. The 
French registry (FRANCE 2)20 demonstrated equally good 1-year survival rates 
when using a frugal approach to TAVR: three quarters of procedures were per-
formed in the catheterization laboratory (as opposed to a hybrid operating suite) 
and a transarterial approach was used in >80%. Of those, local anaesthesia was 
used in >40% and fully percutaneous arterial access site closure was routine. In 
>15% of patients, decision to undergo TAVR (as opposed to SAVR) was solely based 
on patients’ preference (as opposed to high surgical risk).  
 The European SOURCE registry8 compared outcomes of transfemoral and 
transapical groups adjusted to their respective risk score, showing better outcomes 
with the transfemoral approach. Stroke rates were lower in this real-world registry 
(2.5% at 30days and 4.5% at 1 year), as compared to the PARTNER Trial. 
 The Canadian experience21 reported equal use of the transfemoral and trans-
apical route with similar outcomes between the two. They defined high-risk sub-
groups with worse outcome to be patients suffering from chronic obstructive pul-
monary disease and chronic kidney disease, while patients with porcelain aorta 
showed better long-term outcomes. 
 A subgroup of TAVI patients that are of particular concern are patients suffer-
ing from atrial fibrillation: outcome in those patients is worse as compared to pa-
tients in sinus rhythm, for reasons that are not fully understood22.  
 In summary, TAVR has established as an excellent alternative to SAVR with an 
at least comparable outcome. The focus has diverted away from reasonability to 
improving outcome and maybe moving towards lower risk populations. This bodes 
well for the new procedure. How can we try to further improve outcomes of TAVR? 
The most devastating complication is the occurrence of a major stroke: can we 
further reduce the stroke rate? In particular: what is the role of cerebral protec-
tion devices? Left atrial appendage occlusion (LAAO) is an attractive treatment 
option for TAVR patients in atrial fibrillation, typically being exposed to a high 
bleeding risk. What are the long-term outcomes after LAAO? Do long-term out-
come data justify the combination of TAVR and LAAO to potentially improve out-
comes in this high-risk population? And: what can we learn from pathology stud-
ies in TAVR patients? Can the transcatheter valves be expected to be as durable as 
bioprosthetic surgical valves? What are the mechanisms of heart-block and are 
P A R T  1  
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there other – unexpected – pathology findings? Can we reduce invasiveness of the 
transapical procedure, thereby potentially improving outcomes? I will try to ad-
dress some aspects of these important issues in the following chapters. 
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2.1.1. An embolic deflection device for 
aortic valve interventions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fabian Nietlispach MD, Namal Wijesinghe MD, Ronen Gurvitch MD, Edgar Tay MD, 
Jeffrey P. Carpenter, MD, Carol Burns, RN, John G. Webb MD 
 
J Am Coll Cardiol Intv 2010;3:1133-8. 
  
P A R T  2  
 20 
Abstract 
 Objectives. We describe initial human experience with a novel cerebral embol-
ic protection device. 
 Background. Cerebral emboli are the major cause of procedural stroke during 
percutaneous aortic valve interventions.  
 Methods. Utilizing right radial artery access the embolic protection device is 
advanced into the aortic arch. Once deployed a porous membrane shields the bra-
chiocephic trunk and the left carotid artery deflecting emboli away from the cere-
bral circulation. Embolic material is not contained or removed by the device. The 
device was utilized in 4 patients (mean age 90 years) with severe aortic stenosis 
undergoing aortic balloon valvuloplasty (n=1) or transcatheter aortic valve implan-
tation (TAVI) (n=3).  
 Results. Correct placement of the embolic protection device was achieved 
without difficulty in all patients. Continuous brachiocephalic and aortic pressure 
monitoring documented equal pressures without evidence of obstruction to cere-
bral perfusion. Additional procedural time due to the use of the device was 13min 
(IQR 12-16). There were no procedural complications. Pre-discharge cerebral mag-
netic resonance imaging found no new defects in any of 3 patients undergoing TAVI 
and a new 5mm acute cortical infarct in 1 asymptomatic patient following balloon 
valvuloplasty alone. No patient developed new neurological symptoms or clinical 
findings of stroke.  
 Conclusion. Embolic protection during transcatheter aortic valve intervention 
appears feasible and may have the potential to reduce the risk of cerebral embolism 
and stroke.  
 
Abbreviations:  
TAVI = Transarterial aortic valve implantation 
cMRI = Cranial magnetic resonance imaging 
 
 
 
 
 
  
C U R R E N T  P R O B L E M S  A N D  U N S O L V E D  I S S U E S  
 21 
Introduction 
Transcatheter aortic valve interventions are associated with a risk of cerebral em-
bolism and stroke. Atheroembolism may occur as a consequence of traumatic pas-
sage of wires and catheters around an atheromatous aortic arch 1. Calcific embolism 
may occur when the endothelial covering of a degenerated aortic valve is disrupted. 
Thromboembolism may occur during any interventional procedure. Aortic balloon 
valvuloplasty has been associated with a stroke rate of 1 to 4% 2 3 4 5. Transcatheter 
aortic valve implantation (TAVI) has been associated with a stroke rate of 1.9-
4.2% 6 7.  
 
Clinical stroke may represent one end of the spectrum of cerebral embolism. Recent 
studies suggest that subclinical cerebral embolic events are common 8 9-11. Cranial 
magnetic resonance imaging (cMRI) has demonstrated an incidence of new cerebral 
lesions in 22% of elderly high risk patients undergoing diagnostic catheterization 
with crossing of the aortic valve 12 and recent studies found that 73-84% of patients 
undergoing TAVI had new cerebral lesions on cMRI 13 14. The clinical importance of 
asymptomatic new cMRI lesions is unknown, but remains a concern 8, 15 16 17. 
 
Cerebral protection devices exist for carotid interventions 18 and may lead to a 60% 
reduction of brain embolism. Other devices are currently under investigation for 
surgical aortic valve replacement 19. We report our first-in-human experience with 
the Embrella Embolic DeflectorTM (Embrella Cardiovascular Inc, Wayne, PA) device 
which is designed to reduce the number of cerebral emboli in percutaneous aortic 
valve interventions. 
Methods 
Patients 
The device was used in 4 patients with severe symptomatic aortic stenosis. All pa-
tients underwent balloon aortic valvuloplasty and in 3 patients this was followed 
by TAVI. Pre- and postprocedural cMRI studies were performed. All patients were 
reviewed with a senior team of cardiologists and cardiac surgeons and had been 
declined for open aortic valve replacement due to age and co-morbidities. Proce-
dures were approved by the Department of Health and Welfare, Canada and pa-
tients gave written informed consent for TAVI, balloon aortic valvuloplasty and the 
use of the Embrella Embolic DeflectorTM. 
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Embrella Embolic DeflectorTM 
The device is designed to cover the ostia of the brachiocephalic trunk (and its right 
carotid branch) and the left carotid artery originating directly from the transverse 
aorta, thereby deflecting emboli away from the cerebral circulation. Deflecting pet-
als consist of a heparin coated polyurethane membrane with 100micron sized 
pores. This membrane is mounted on a Nitinol® frame, which itself is attached to a 
110cm long 0.035inch (0.09cm) Nitinol® shaft (Figure 1A). When deployed, the 
petals of the device extend over a length of 58mm with a width of 25mm. Three 
radiopaque markers help for fluoroscopy-guided deployment: one at the outer 
point of each petal and one on the distal shaft (Figure 1B). The entire system can be 
delivered through a 6 French delivery sheath introduced from the right arm. 
 
 
Figure 1. Embrella Embolic DeflectorTM 
A. The device consists of a porous membrane (black arrow), a nitinol frame (striped arrow) and a nitinol
shaft (white arrow). B. Two radiopaque markers indicate the end of each petal (black arrows) and one
radiopaque marker at the end of the shaft help proper alignment of the device with the tip of the sheath 
(white arrow). 
 
Patients were pre-treated with clopidogrel 600mg and aspirin 325mg at least 2 
hours prior to commencement of the procedure. In all patients a standard 6 F 
sheath was placed in the right radial artery following which heparin was given so as 
to achieve an activated clotting time above 300 ms. A 0.035” J-tipped guidewire was 
advanced to the aortic arch over which was passed a 90cm long 6 French Shuttle SL 
sheath (Cook Medical, Stouffville, ON, Canada). After confirming integrity of the 
devices’ porous membrane by visual inspection, the device was retracted into a 
loading tool, flushed and subsequently introduced into the sheath. With the tip of 
the sheath in the aortic arch the device was slowly released under fluoroscopic 
guidance. Deployment of the two petals each in the opposite direction (one towards 
the ascending aorta, the other towards the distal aortic arch) without deformation 
of the petals was assured (Figure 2). The device was then retracted towards the 
sheath so that the distal marker on the sheath aligned with the radiopaque marker 
on the device shaft (Figure 3A and B). In this position the device and sheath were 
pulled back as to cover the ostia of the brachiocephalic trunk and the left common 
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carotid artery, adjacent to the greater curvature of the aortic arch (Figure 3C). Cor-
rect device position was confirmed if contrast injections through the delivery 
sheath led to temporary dye pooling over the brachiocelphalic and left carotid ostia 
adjacent to the overlying device (Figure 3C). Pressure was measured continuously 
from the side port of the delivery sheath (representing brachiocephalic pressure 
distal to the Embrella device) and from a pigtail in the ascending aorta (represent-
ing pressure proximal to the Embrella device) to ensure that cerebral perfusion 
was maintained at all time (Figure 4).  
 
 
Figure 2. Deployment of the Embrella Embolic DeflectorTM 
A. The two petals are oriented in the opposite direction. B. Further deployment with the two petals fully 
opened. 
 
 
Figure 3. Final positioning of the Embrella Embolic DeflectorTM 
A and B. The radiopaque marker on the shaft has to be aligned with the radiopaque marker on the tip of
the sheath. C. The sheath and the device are retracted to cover the ostia of the brachiocephalic trunk and
the left common carotid. Contrast collects transiently on the distal side of the petals, indicating correct
positioning. 
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Figure 4. Continous pressure recording proximal and distal to the device 
Three pressure tracings were continuously recorded: aortic pressure
(green), brachiocephalic pressure (blue) and femoral pressure (purple).
There was no pressure gradient across the device. 
Aortic valve intervention 
Balloon valvuloplasty was performed utilizing a balloon (NucleusTM, NuMed Inc, 
London, ON, Canada) with a nominal diameter equal to the echocardiographic di-
ameter of the aortic annulus. TAVI was performed in a standard manner utilizing an 
Edwards SAPIEN valve and Retroflex 3 delivery system (Edwards Lifescience Inc, 
Irvine, CA, USA) 20. Percutaneous femoral access was utilized. A 14 French arterial 
sheath was utilized in the 1 patient undergoing valvuloplasty alone, a 24French 
sheath (for the 26mm Edwards SAPIEN valve) was used in 2 patients and a 
22French sheath (for the 23mm Edwards SAPIEN valve) in 1 patient. Percutaneous 
puncture with pre-closure of the femoral access site (ProGlide, Abott Vascular, Ab-
bott Park, IL, USA) was routine. Rapid pacing during balloon valvuloplasty and TAVI 
was routine. General anaesthesia with transesophageal echo-guidance was utilized 
in all TAVI procedures.  
Statistics 
Given the small study population all data are presented as median and interquartile 
ranges (IQR). No group comparisons were performed. 
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Results 
Baseline characteristics 
Median age was 90years (IQR 87-92), 3 male and one female. Risk factors for stroke 
included peripheral vascular disease in 2, prior stroke in 3, hypertension in 3, 
dyslipidemia in 2, none suffered diabetes or was a smoker and none had severe 
ascending aorta calcification 21. Fluoroscopic calcification of the ascending aorta 
was graded mild in all and fluoroscopic valvular calcification was graded 3+ (dense 
circumferential calcification) in 3patients. 
Procedural outcome 
Correct placement of the Embrella Embolic DeflectorTM with the deflecting petals 
covering the brachiocephalic and left carotid artery ostia was achieved in all 4 pa-
tients. The device appeared to be self-aligning within the transverse aorta and did 
not require manipulation beyond withdrawal so as to appose the outer curvature of 
the aortic arch. Contrast injection through the delivery sheath confirmed transient 
pooling in the arch vessels distal to the deflector. Radial and aortic monitoring 
showed no significant reduction in perfusion pressure and did not vary through the 
course of the procedure (Figure 4).  
 
Advancement of wires, pigtail catheters, valvuloplasty balloons and the relatively 
bulky valve delivery system alongside the Embrella device was associated with 
minimal interaction without significant interference or dislodgement of the device 
(Figure 5). In one case a wire and pigtail catheter appeared to pass behind the de-
flector. This was corrected with further withdrawing the deflector so as to improve 
apposition of the device. At the end of the valve procedures, the deflector was easily 
withdrawn into the delivery sheath and removed. Hemostasis was accomplished 
with a standard radial compression band. Device inspection showed no evidence of 
visible damage or adherent thrombus or embolic material (Figure 6). The total 
procedural time was 91.5 min (IQR 83-97). Total time for insertion of the radial 
sheath, subsequent exchange for the Shuttle SL sheath and insertion, placement and 
finally retrieval of the Embrella device was 13min (IQR 12-16). The Embrella de-
flector was deployed (‘device in patient’) for a total of 42 min (IQR 39-50).  
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Figure 5. Minimal device interference 
No dislodgment or interference occurred 
during passage of the device with the 
valve delivery system. 
 
Figure 6. Device integrity 
No damage to the device was observed 
after retrieval. 
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Clinical outcome 
Clinical assessment before hospital discharge did not reveal any new neurologic 
symptoms. No procedural complications occurred, in particular there were no 
complications related to insertion of the Embrella device. Pre-discharge cMRI 
showed a 5mm acute cortical infarct in the right temporal lobe in the patient that 
underwent balloon aortic valvuloplasty alone. No patient undergoing TAVI had a 
new finding on pre-discharge cMRI. 
Discussion 
Our first-in-human experience demonstrates that cerebral embolic protection dur-
ing transcatheter aortic valve interventions is feasible and can be accomplished 
without significantly interfering with or prolonging what is an already complex 
procedure.  
 
The Embrella device has a number of advantageous features. It can be introduced 
easily from the radial artery with minimal interference with the course of the TAVI 
procedure. Protection during the entire course of a TAVI procedure is feasible. A 
single device provides protection for the right carotid and right vertebral branches 
of the brachiocephalic artery and the left carotid artery. In some patients the device 
may also overlie the left subclavian ostium, providing protection for the left verte-
bral. As the device is not positioned within the cerebral vessels the risk of arterial 
spasm, injury, thrombosis or transiently impaired cerebral perfusion appears min-
imal.  
 
Cerebral emboli originating from the aortic valve and proximal aorta are likely the 
major mechanism of stroke in the setting of aortic valve intervention 12-14. Although 
stroke rates were relatively high in the early TAVI experience the reported risk of 
stroke seems to be falling, perhaps due to the development of less traumatic valve 
delivery catheters 22, 23, improved technique and patient selection. Nevertheless 
recent TAVI series continue to report a 1 to 4% risk of clinical stroke associated 
with significant morbidity and mortality 6, 7, 23. 
 
Several lines of evidence suggest that reported stroke rates may underestimate the 
clinical importance of cerebral embolism. Early experience with transcranial Dop-
pler and post-procedural cMRI 13, 14 suggest that cerebral embolism is more the 
norm than the exception with TAVI even in the absence of clinical deficits. Compa-
rable experience with carotid stenting suggest microemboli play a role in memory 
loss and other neurocognitive syndromes 24 25. Several studies suggest that cerebral 
protection during carotid interventions may reduce cerebral embolism and im-
prove outcomes 26 27 18 28.  
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The current study documents use of the Embrella device in the setting of TAVI. 
However other potential applications can be envisioned. Open heart or aortic sur-
gery in the presence of aortic atheroma or intra-cardiac thrombus and mitral val-
vuloplasty or atrial appendage closure in the presence of left atrial thrombus may 
represent additional potential applications for cerebral protection.  
Limitations 
Given the small number of patients our experience can only be considered a proof 
of concept. Further studies will be required to document safety and efficacy. All our 
patients had type II aortic arch anatomy with the right subclavian and right carotid 
artery originating from the brachiocephalic trunk. The importance of variation in 
aortic arch anatomy is unknown as the applicability of this device in patients un-
dergoing aortic valve interventions utilizing different interventional devices and 
routes of access (eg. transaxillary or transapical). The risk of device thrombosis in 
the presence of suboptimal anticoagulant and antiplatelet therapy and prolonged 
dwell time are unknown. An obvious concern is that this device does not trap em-
boli or allow for their removal. Instead emboli are deflected into the descending 
aorta. Although cerebral embolization may be reduced embolization to the periph-
ery, kidneys and bowel may be correspondingly increased. Theoretically the clinical 
consequences are less with peripheral micro-embolism, however this remains to be 
demonstrated.  
Conclusion 
The use of an aortic embolic deflector system appears feasible and is compatible 
with clinical aortic valvuloplasty and transcatheter valve implantation. The proce-
dure appears safe with minimal additional time requirements. The Embrella Em-
bolic Deflector is a promising device that may improve the outcomes of TAVI. Fur-
ther studies are required to further assess safety and efficacy. 
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Abstract 
Transcatheter aortic valve implantation is a widely performed procedure for treat-
ment of symptomatic severe aortic stenosis. 
 According to the current literature, major stroke has been reported to occur in 
3-6% of the patients during the first 30 days following valve implantation. Several 
pathological mechanisms may be involved in the development of periprocedural 
ischemic stroke with the majority being due to thrombo- and atheroembolism. One 
approach to reduce the incidence of procedural cerebral thromboembolic events is 
the use of cerebral protection devices, either deflecting (Embrella, TriGuard) or 
capturing (Claret, Embol-X) embolic material.  
 We sought to review the current evidence on this important issue focussing on 
the four cerebral protection devices currently available.  
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Introduction 
Since the publication of the randomized PARTNER trials in 2010 and 2011 
transcatheter aortic valve implantation (TAVI) has become a widely performed 
treatment for patients suffering from symptomatic severe aortic stenosis (AS). The 
first published PARTNER B trial established the superiority of TAVI over medical 
treatment in inoperable patients showing a highly significant reduction of all-cause 
mortality at 1 year (43.3% vs. 68.0%; p<0.001), paralleled by a markedly improved 
quality-of-life (1). However, there was a non-significant trend towards more major 
strokes in the transcatheter group (5% vs. 1.1% in the medical group at 30 days; 
p=0.06).  
 In the PARTNER A trial, patients with severe AS at high risk for surgery were 
randomized to either transfemoral / transapical TAVI or surgical aortic valve re-
placement (SAVR). TAVI proved to be non-inferior as compared to SAVR with re-
gard to all-cause mortality. Thirty-day mortality was even significantly lower in the 
subgroup of patients undergoing transfemoral TAVI (3.7 vs 8.2%, as-treated-
analysis)(2). Peri- and post-procedural morbidity differed considerably between 
the two treatment modalities: while neurologic events and vascular complications 
occurred more often in the TAVI group, the SAVR population suffered from more 
major bleedings and experienced more new-onset atrial fibrillation. The rate of 
major strokes did not differ between the treatment groups, and after 30 months(3), 
numerically more strokes had occurred in the SAVR population. According to a 
2012 published meta-analysis including more than 10’000 patients, 30-day neuro-
logic event rate was 3.3±1.8% (range 0-6%) with a 3.5-fold increase in 30-day mor-
tality in patients experiencing a stroke (25.5±21.9% vs. 6.9±4.2%)(4). Therefore, 
stroke prevention is an important issue.  
Pathogenesis of stroke in TAVI 
Cerebral imaging studies reported silent ischemic lesions (mostly multiple) in 68-
91% of patients a few days after TAVI(5-7). These lesions were not associated with 
symptoms or measurable cognitive impairment and 80% of the detected lesions 
disappeared after 3 months(8). 
 Several mechanisms may be involved in the pathogenesis of periprocedural 
stroke in TAVI including embolization of calcified or atheromatous particles, 
thrombo- and air embolism, as well as prolonged hypotension and haemorrhage. 
Histopathological analyses of fragments captured during TAVI demonstrated 
thrombotic material (fibrin) and fragments compatible with aortic valve leaflet 
or aortic wall origin (amorphous calcium, and connective tissue) in the majority of 
cases(9).  
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During TAVI procedural steps associated with manipulation of the aortic valve may 
cause most of the cerebral embolisms. Simple retrograde passage of the stenotic 
aortic valve with diagnostic catheters is associated with silent cerebral embolism in 
22% of patients(10). Transcranial Doppler (TCD) studies during TAVI confirmed 
the majority of cerebral microembolisms occurring at the time of balloon valvulo-
plasty, deployment and positioning of the prosthetic valve(11, 12). This may ex-
plain why intra-procedural neurologic events are not more common in transfemo-
ral procedures as compared to transapical TAVI, despite the theoretical advantage 
of sparing the aortic arch when a transpical approach is chosen(6, 13). 
 Only 40-50% of symptomatic strokes occur within 24 hours after TAVI(14, 15), 
resulting in more than half of the strokes not being directly procedure related. 
 Established risks factors for early stroke include small aortic valve area, prior 
history of cerebrovascular accidents, balloon postdilatation, multiple valve implan-
tation attempts, and (new onset) atrial fibrillation(14-17). The incidence of stroke 
continues to be high, up to 60 days after valve implantation followed by a low but 
constant risk during long-term follow-up, mainly influenced by individual risk fac-
tors (e.g. BMI<20kg/m2, age>80 years, chronic atrial fibrillation and peripheral and 
cerebrovascular disease)(17, 18).  
Requirements for cerebral protection devices 
The goal of a cerebral protection device is to prevent clinical relevant intraproce-
dural strokes. As stroke is a rare complication, silent new cerebral lesions as as-
sessed by diffusion-weighted MRI (DW-MRI) or high intensity transient signals 
(HITS) detected by transcranial Doppler are often used as endpoints in studies. The 
clinical meaning of new perfusion defects, however, remains a matter of controver-
sy. According to surgical literature, the lesion “load” detected by MRI has been as-
sociated with postoperative cognitive decline(19) - a relation that has not been 
confirmed in patients undergoing TAVI(8, 20).  
 Evidence from carotid stenting and open-heart surgery suggests that mechani-
cal cerebral protection has the potential to reduce stroke rate and to improve clini-
cal outcome(21, 22). 
 Despite these theoretical advantages when using cerebral protection devices, 
positioning of the device in the aortic arch itself carries a certain risk of mobilizing 
atheromatous material and causing damage to the arterial wall, possibly resulting 
in a neurologic event. This makes an excellent safety profile and the use of anti-
thrombogenic material the most important requirements for cerebral protection 
devices. Furthermore, protection devices are expected to warrant stable position, to 
fit anatomical variations of the aortic arch, to allow sufficient perfusion of the pro-
tected arterial territories, and to avoid interference with valve delivery. Deploy-
ment has to be simple and fast in order not to lengthen and complicating the TAVI 
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procedure. There are currently four devices in investigational use potentially meet-
ing these requirements (Table 1). 
 
Table 1: Overview of the currently available cerebral protection devices 
 Access Delivery Principle Studies (n)
Embrella radial/brachial 6 French deflection FIH (4)
PROTAVI-C Pilot Study (41)* 
Triguard femoral 7/9 French deflection FIH (15)
DEFLECT I (28)* 
Montage radial/brachial 6 French capture FIH (40)
Histopathological Study (40) 
Embol-X transaortic (surgical) 14 French capture RT in surgical patients 
CR in TAVI (1) 
n: number of patients included; FIH: first-in-human; RT: randomized trial; CR: case report; *: un-
published data 
Currently available cerebral protection devices 
1) Embolic deflection devices 
The Embrella device (Edwards Lifesciences Ltd., Irvine, CA, USA), introduced via 
radial or brachial arterial access, deflects emboli from the innominate and the left 
carotid artery. In 60% of patients the device additionally covers the left subclavian 
artery. The device consists of two hydrophilic heparin-coated polyurethane mem-
branes with 100 μm pores. An oval umbrella-like nitinol frame holds the mem-
branes and is attached to a 0.035” (0.89mm) nitinol cable (Figure 1). After intro-
duction of a 6F long delivery sheath through the radial or brachial artery to the 
aortic arch, the Embrella device is advanced under fluoroscopic guidance, exited 
the sheath in the aortic arch, where the two petals of the umbrella are stabilized at 
the outer curvature (Figure 2). 
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Figure 1. The Embrella device consists of an umbrella-like nitinol frame 
holding two polyurethane membranes (Courtesy of Edwards Lifesciences 
Ltd., Irvine, CA, USA.) 
 
Figure 2. Embrella device positioned at the inner curvature of the aortic 
arch. The device fully covers the brachiocephalic trunk (arrow), the left 
carotid artery (*), and the left subclavian artery (**); Ao: Aorta 
 
A 2010 published first-in-human study in 4 patients confirmed feasibility of the 
device use(23). Currently, a double randomized trial is ongoing in Europe and Can-
ada (PROTAVI-C for Prospective Randomized Outcome study in patients undergo-
ing TAVI to Examine Cerebral Ischemia and Bleeding Complications). The study 
aims to investigate the efficacy of the Embrella device for prevention of new in-
traprocedural cerebral lesions (assessed by diffusion-weighted MRI) in 500 pa-
tients. In a second post-procedural phase, the patients will be randomly allocated to 
either single or dual antiplatelet therapy and followed for 1 year. The results of the 
PROTAVI-C Pilot Study were presented at EuroPCR 2013: in 41 patients the Em-
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brella device was successfully deployed and retracted. One patient suffered a non-
device related minor stroke on day two. On DW-MRI, all (100%) patients showed 
new ischemic lesions. However, the lesion volume was markedly smaller as com-
pared to patients where no cerebral protection was used. Intraprocedural tran-
scranial doppler showed most HITS during valve crossing and prosthesis position-
ing, closely followed by a high number of HITS during deployment of the device. 
 
The TriGuard Cerebral Protection Device (Keystone Heart Ltd, formerly SMT 
Research & Development Ltd, Caesarea, Israel) is introduced via the femoral artery. 
The concept is similar to that of the Embrella device with some notable differences. 
A 9F sheath is usually used for delivery and retrieval and allows additional place-
ment of a pigtail catheter for procedural guidance. The device itself consists of a 
nitinol mesh and a nitinol frame with two stabilizers that anchor the device in the 
brachiocephalic trunk and at the inner curvature of the aortic arch (Figure 3). The 
system was first designed as a permanent surgical implant for cerebral protection 
in patients at high risk for recurrent embolisms. 
 
Figure 3. a: The TriGuard Cere-
bral Protection Device consists of
a porous membrane and a nitinol
frame with two stabilizers (ar-
rows) (Courtesy of Keystone
Heart Ltd, Caesarea, Israel) 
b: Device anchored in the brachi-
ocephalic trunk and at the inner
curvature of the aortic arch. The
design allows coverage of all
three neck vessels (Courtesy of
Keystone Heart Ltd, Caesarea,
Israel) 
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Initial experience in 15 patients proved feasibility(24) of the device use. At Eu-
roPCR 2013 preliminary results from the prospective DEFLECT I Trial were pre-
sented: initial device positioning was successful in 100% of patients. However, after 
removal of the TAVI delivery system, only 79% of devices were still correctly posi-
tioned and only 68% of devices still covered all three neck vessels. Of the 28 study 
patients none had adverse clinical events associated with the device use, while 2 
suffered a non-device related stroke on day 1 after TAVI. The total number of pa-
tients with new ischemic cerebral lesions on DW-MRI was not reduced significantly 
as compared to historical cohorts where no cerebral protection device was used 
(70% vs. 76%), while the total volume of the new lesions was reduced in patients 
where the TriGuard was used (1.64 cm3 vs. 0.70 cm3). 
2) Embolic capture devices 
The Montage Dual Filter System (Claret Medical Inc., Santa Rosa, CA, USA) is de-
signed to capture embolic debris travelling to the brain in the brachiocephalic trunk 
and the left common carotid arteries (Figure 4). The catheter is delivered through a 
6F sheath via the radial or brachial artery. The conically shaped filters consist of a 
nitinol frame and polyurethane laser drilled filter membrane with 140 μm diameter 
pores. The filter frames are radiopaque and once deployed seal against the vessel 
wall allowing filtered blood to pass to the brain while trapping debris. After posi-
tioning of the first filter in the brachiocephalic trunk, the catheter is advanced fur-
ther in the aortic arch under fluoroscopic guidance and the tip of the delivery sys-
tem is curved towards the left common carotid artery for placement of the second 
filter. Anatomical requirements are a diameter of the brachiocephalic trunk meas-
uring between 9-16mm and a left common carotid artery diameter between 6-
10mm. Recent improvements over the first generation device include compatibility 
with 0.014” standard coronary guidewires, a modified curve of the device tip to 
simplify antegrade intubation of the left carotid artery, hydro-coating, and imple-
mentation of an ergonomic handle. The safe use of the system has been demon-
strated in a 2012 published first-in-man study, which included 40 patients (7 pa-
tients received the first generation device and 33 patients the second generation 
device). Successful placement of both filters was achieved in 60% of patients with 
the first generation and in 87% of patients with the second-generation device. Em-
bolic debris was collected in 54% of patients at termination of the TAVI procedure. 
Complications directly related to device insertion occurred in 4 patients (10%) 
requiring surgery in 3 patients (7.5%) (1 dissection of the radial artery and 2 bra-
chial pseudoaneurysms). Early stroke (<24h) was reported in one patient 
(2.5%)(25). In another study exclusively using the second-generation device, tech-
nical success was 100% without any device-related complications. Macroscopic 
debris was captured in at least one of the two filters in 75% of the cases(9). To date, 
no data exist on the potential reduction of cerebral embolisms when using the de-
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vice (e.g. by means of reduction of HITS on TCD or new –ischemic lesions on DW-
MRI). A larger multicentre randomized trial filling this gap is currently pending. 
 
 
Figure 4. a: Angiographic view of the Montage Dual Filter System successfully positioned in the brachio-
cephalic trunk (*) and the left carotid artery (**) (Courtesy of Claret Medical Inc., Santa Rosa, CA, USA) 
b: The device consists of two conically shaped polyurethane filters and a nitinol frame. The proximal
filter (*) is deployed in the innominate artery and the distal filter in the left carotid artery (**); Ao: Aorta
(Courtesy of Claret Medical Inc., Santa Rosa, CA, USA) 
 
The Embol-X intra-aortic filter (Edwards Lifesciences Ltd., Irvine, CA, USA) was 
designed for surgical use. In surgical patients the device is introduced via a sidearm 
of a modified 24F intra-aortic cannula and deployed in the ascending aorta before 
removal of the aortic clamp (Figure 5). It remains in place as long as the patient is 
on cardiopulmonary bypass. The filter consists of a polyester mesh capturing debris 
>120µm and is currently available in 5 different sizes fitting internal aortic diame-
ters of 2.2 to 4.0cm. In a randomized trial including almost 1’300 patients undergo-
ing open heart surgery the device demonstrated capture of debris in up to 97% of 
patients. No particular safety concerns were raised. However, no significant differ-
ences in the rate of apparent strokes between the two study groups (2.6% in the 
filter group vs. 2.2% in the control group; p=0.59) were seen. The occurrence of 
silent cerebral lesions has not been investigated. Overall, better outcome was ob-
served in patients with a low body mass index (<25kg/m2), low ejection fraction 
(≤25%) or previous history of cerebrovascular disease. These differences were 
mainly driven by a reduction in postoperative renal failure in the filter group(22). 
 In TAVI, the device can exclusively be introduced through an upper mini-
sternotomy providing direct visualization of the ascending aorta. In 2011, the filter 
was successfully deployed over a 14F sheath in one patient during transaortic TA-
VI(26). At follow-up (48h) the patient developed no silent or apparent cerebral 
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complication. Since the transaortic access is the only TAVI access allowing insertion 
of the Embol-X device, the use in its current design will remain limited in TAVI. 
 
Figure 5. The Embol-X device is introduced via a sidearm of a modi-
fied 24F intraaortic cannula. The polyester mesh (*) captures debris
with a diameter >120µm. 
Conclusions 
Prevention of stroke is an important issue to further improve outcome in TAVI. This 
is particularly true in light of expansion of TAVI from high-risk to intermediate risk 
patients. As an established risk factor for the occurrence of early post-procedural 
neurological events, new-onset atrial fibrillation requires timely diagnosis and 
adequate treatment. Left atrial appendage closure is a very attractive alternative to 
oral anticoagulation in these patients(27, 28).  
 Further, smaller delivery catheters have the potential to further reduce stroke 
rate(29, 30). If a self-expandable valve prosthesis is used, avoiding balloon aortic 
valvuloplasty, eliminates an important source of microembolism during TAVI(31). 
The development of a true percutaneous transapical approach with percutaneous 
apical closure(32) may be less traumatic and improve outcome of the transapical 
TAVI.  
 It is of note, that only about 50% of the cerebrovascular events observed during 
the 30-days period following TAVI are believed to occur during the procedure itself, 
while the reminder of strokes occurred weeks to months after implantation. As a 
consequence, defining the most appropriate antiplatelet or anticoagulation regimen 
and its duration following TAVI may have a significant impact on stroke rate what 
makes medical therapy an important pillar of stroke prevention after TAVI. Me-
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chanical cerebral protection has the theoretical potential to reduce procedural 
stroke rate at most by 50%. Besides local complications at the insertion site, results 
from the PROTAVI-C Pilot Study confirms that placement of the device itself carries 
a risk of causing cerebral embolism. From preliminary results of the DEFLECT I trial 
we learn, that there is a risk of device-interference with the valve delivery system. 
Whether a reduction in lesion volume justifies the risk of causing potential harm 
will hopefully be answered at termination of the studies. 
 At this stage, broad use of cerebral protection devices during TAVI cannot be 
recommended and their use should - outside of a clinical trial - be restricted to pa-
tients at very high-risk for embolic events (e.g. patients with mobile structures on 
the aortic valve). 
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Part 2  
Current problems and unsolved issues 
2.2. Stroke prevention in patients with 
atrial fibrillation: left atrial 
appendage occlusion 
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2.2.1. Percutaneous Left Atrial Appendage 
Closure 
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Abstract 
 Introduction. Atrial fibrillation is a growing epidemic in the western world. 
Stroke as the most dreaded complication is effectively prevented by oral anticoagu-
lation. Although effective in preventing stroke, they come at a price of bleeding 
complications. Concerns about bleeding lead to a high rate of drug discontinuation 
and is the reason many patients are not put on oral anticoagulants at all. Percuta-
neous left atrial appendage (LAA) closure is an excellent option for patients who 
cannot or who do not want to be on blood thinners, since the left atrial appendage 
is the origin of >90% of clots arising from the left atrium. 
 Methods. Using femoral venous access, a plug is placed in the left atrial ap-
pendage, thereby excluding this embryologic remnant from the circulation. The 
procedure can be performed on an outpatient basis. We report our own experience 
in 100 patients using the Amplatzer Cardiac Plug. 
 Results. 100 patients (72±10 years) underwent LAA closure using only local 
anesthesia without transesophageal guidance. Imaging and sizing of the LAA was 
performed by contrast injections through the 13 French TorqVue delivery sheath, 
followed by device implantation. Clopidogrel was prescribed for 1 month and ace-
tylsalicylic acid for 3-6 months. The procedure was successful in 98% of patients 
and was often performed in conjunction with other interventional procedures. 
Periprocedural complication rate was 6% (2% pericardial effusion, 2% device em-
bolization, 2% transient neurologic symptoms) with no long-term sequelae. 
 Conclusion. LAA closure is an attractive alternative to oral anticoagulation in 
patients suffering from atrial fibrillation. 
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Introduction 
Left atrial appendage closure is the latest achievement in stroke prevention in in-
terventional cardiology. It joins carotid stenting1 and the patent foramen ovale 
(PFO) occlusion2. 
Atrial fibrillation 
Atrial fibrillation (AF) is the most common arrhythmia and a growing epidemic in 
the aging western population: while its prevalence is 0.1% in patients <55 years, it 
increases to 9% in patients aged 80 years or older3 and it is predicted that by the 
year 2050, the prevalence will be more than doubled4.  
 
AF can be asymptomatic, come along with symptoms such as palpitations or dysp-
nea, cause heart failure, and reduce quality of life. The main concern in patients 
suffering atrial fibrillation is, however, a 5-fold increased risk of thromboembolic 
stroke5. The individual annual stroke risk in patients suffering atrial fibrillation 
varies from 0.7% to 14.2%, as reflected in the CHA2DS2-VASc Score, a scoring sys-
tem based on the refined 2006 Birmingham stroke risk schema6.  
 AF associated stroke is the most devastating stroke subtype. It has a high 30-
day mortality (25%) and is associated with significant permanent disability in 60% 
of patients. 
Oral anticoagulation 
Oral anticoagulation using vitamin K antagonists is a highly effective treatment 
with a relative risk reduction (RRR) for stroke of around 64% as compared to pla-
cebo, and of 22% as compared to acetylsalicylic acid7. The advantage of oral antico-
agulation is more pronounced in the elderly population8. 
 
With the introduction of the CHA2DS2-VASc Score, which accounts for atheroscle-
rotic disease as a stroke risk factor and puts more weight on advanced age than the 
former CHADS2 score, more patients qualify for oral anticoagulation: 91.5% of AF 
patients are in the intermediate or high risk group for stroke, warranting oral anti-
coagulation (as compared to 79.6% when using the CHADS2-Score)6. 
 
Although effective, oral anticoagulation has limitations and drawbacks: the small 
therapeutic window leaves us with an increased risk for stroke or intracranial 
hemorrhage in case of sub- or supratherapeutic doses (incidence up to 9.4/100 
patient years)9. In a study setting, the predefined therapeutic International Normal-
ized Ratio (INR) of 2.0 – 3.0 was achieved in only 60%-77% of the time10. In the real 
world, this percentage is even lower. 
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Besides intracranial hemorrhages, gastrointestinal (GI) bleeding is another serious 
side effect of oral anticoagulants. Mortality from GI bleeding ranges from 1-
13%11,12, while oral anticoagulation not only serves as a risk factor for bleeding, but 
further increases bleeding related morbidity13. 
 
To assess the risk of bleeding in a patient on vitamin K antagonists the HAS-BLED 
score14 was developed. It defines risk factors for bleeding to be hypertension, ab-
normal renal or liver function, age >65 years, stroke or bleeding in the past, labile 
INRs, alcohol or drug intake (e.g. non-steroidal antirheumatic drugs). Each of these 
account for one point. A score of 3 or more puts a patient in the high-risk popula-
tion. Other risk factors are diabetes, heart failure, decreased left ventricular func-
tion, or concurrent use of acetylsalicylic acid15. On average, in patients on vitamin K 
antagonists the annual risk for major bleeding is 3% with the annual incidence of 
overall bleeding complications summing up to 10%16.  
 
New oral anticoagulants. The new oral anticoagulants recently introduced may 
improve on that. They are rivaroxaban, apixaban (oral factor Xa inhibitors), and 
dabigatran (direct thrombin inhibitor). 
 
The three landmark studies compared the new oral anticoagulants to vitamin K 
antagonists and included each 14.000 to 18.000 patients suffering from atrial fibril-
lation10,17,18. They were able to show a relative risk reduction for the combined 
endpoint of stroke or systemic embolism of 21 - 34%/year. The absolute risk re-
duction was rather modest (0.16 - 0.6%/year), pointing out that it had indeed been 
necessary to include such large numbers of patients to show an advantage over 
vitamin K antagonists. 
 The higher efficacy came at a price: Major gastrointestinal bleeding was signifi-
cantly more frequent in patients treated with rivaroxaban, as compared to vitamin 
K antagonists (3.2% vs 2.2%). The same was found in patients treated with higher 
doses of dabigatran (1.5% vs 1.02%), but not with the lower dose of dabigatran or 
with apixaban. The higher, but not the lower dose of dabigatran was more efficient 
in reducing stroke and embolism when compared to vitamin K antagonists. Overall 
major bleeding was not more common neither in patients on high dose dabigatran, 
nor in patients on rivaroxaban or apixaban as compared to vitamin K antagonists. 
With apixaban and the lower dose of dabigatran it was even significantly less com-
mon. Moreover, cerebral bleeds were significantly reduced by all new oral antico-
agulants. Thus, it is the gastrointestinal tract but fortunately not the head that 
seems prone to bleeding when the more efficacious newer drugs are used.  
 
Even with the newer anticoagulants, bleeding remains a concern: major or clinically 
relevant non-major bleeding occurred in 4.1 to 6.0% in patients in the ARISTOTLE-
trial18 and in 14.5 to 14.9% in the ROCKET-AF trial17, while major bleeding oc-
curred in 2.7-3.4% in the RE-LY trial10. The ROCKET-AF Trial included high-risk 
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patients with a mean CHADS2 score of 3.5 and a very high prevalence of bleeding 
risk factors as mentioned above, reflecting a less selected population as compared 
to the two other studies (each with a mean CHADS2 score of 2.1). 
 
Furthermore, even in the trial setting there was a high rate of drug discontinuation, 
ranging from 17% to 27% 10,18. 
Left atrial appendage closure  
Rationale and evidence. As described, >90% of patients in atrial fibrillation are at 
high risk for stroke. While vitamin K antagonists and newer oral anticoagulants are 
effective in reducing the stroke risk, they come at a price of relevant bleeding com-
plications up to 15%/year.  
 Therefore an alternative treatment to reduce stroke risk is and remains neces-
sary and welcome. Acetylsalicylic acid alone or in combination with clopidogrel is 
less effective for stroke prevention in patients with atrial fibrillation than vitamin K 
antagonists. The reason may be that thrombus formation in atrial fibrillation is 
thrombin, rather than platelet mediated. Therefore, the Virchow triad applies: hy-
percoagulability, stasis, and endothelial dysfunction. Besides absence of contractili-
ty in the left atrial appendage (LAA) in patients with atrial fibrillation, the LAA un-
dergoes remodeling leading to dilation, a known risk factor for thrombus for-
mation19 and endothelial dysfunction with a locally prothrombotic and hypercoagu-
lable environment20,21. Not surprisingly, 91% of thrombi in patients with non-
rheumatic atrial fibrillation are therefore found in the LAA22 (Figure 1). 
 
Figure 1. Thrombus in the left atrial appendage 
Thrombus (*) in the LAA – the predilection site for thrombus formation
in patients suffering from atrial fibrillation. 
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The LAA is an embryologic remnant with no known important function. It has a 
variable anatomy with a single or multiple trabeculated lobules and is located ante-
rior and inferior to the left superior pulmonary vein. Given its predilection for 
thrombus formation, exclusion of the LAA from the bloodstream seems a promising 
treatment. 
 
While feasibility of surgical LAA obliteration during open-heart surgery was 
demonstrated23, no study showed non-inferiority of the surgical approach as com-
pared to vitamin K antagonists. The main concern of surgical closure was incom-
plete obliteration, potentially reducing its effectiveness24. As most surgical LAA 
closures were performed in the realm of metallic mitral valve replacement, oral 
anticoagulation had to be continued anyway, precluding a meaningful assessment 
of the preventive affect of LAA closure.  
 
Different devices for percutaneous closure of the LAA were subsequently evaluated 
(Figure 2). The first was the PLAATO device (EV3 Inc, Plymouth, MN)25 in 2001, 
followed by Amplatzer devices (St. Jude Medical, St. Paul, MN)26 and the Watchman 
device (Artritech, Plymouth, MN)27 in 2002. Amplatzer devices have so far been the 
only ones implanted without echocardiographic guidance and hence without the 
compelling need for intubation28.  
 
 
Figure 2. Percutaneous devices for LAA occlusion 
Devices used for LAA occlusion: A: PLAATO device (not longer available), B: Amplatzer ASD Occluder 
(left) and Amplatzer Cardiac Plug (right), C: Watchman device.  
 
The secondary prevention trial PLAATO25 was using the PLAATO system in 111 
patients with a contraindication to vitamin K antagonists and a previous history of 
stroke. After an average follow-up of 10 months, 2 strokes had occurred. Given the 
high-risk population, this was a theoretical 50% relative risk reduction as com-
pared to no therapy.  
 
The PROTECT AF trial27 randomized 707 patients 1:2 to LAA closure with the 
Watchman device and discontinuation of vitamin K antagonists after 90 days. Non-
inferiority in reducing stroke, systemic embolism, and cardiovascular death of the 
device therapy group after an average of 18 months follow-up (3.0 vs 4.9/100 pa-
tient-years) was demonstrated. The initial safety concerns were hushed to a great 
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deal with the same authors publishing combined data on the PROTECT AF trial and 
the ongoing registry29. They showed improving results along the operator learning 
curve. Implant success could be improved with growing experience (91% vs 95%) 
and safety events were reduced (e.g. serious pericardial effusion (4.1% vs 2.2%) 
and procedure related stroke (0.5 vs 0%).  
 
The functional impact (sustained disability) of the adverse events was significantly 
lower in the intervention group than that of the bleeding complications in the vita-
min K antagonist group. 
Devices and technique 
The current percutaneous LAA occluders are deployed using right femoral venous 
access (Figure 3). The right atrium is accessed, followed by a transseptal puncture 
(Figure 3A) or passage through a PFO or atrial septal defect (ASD) to enter the left 
atrium. A delivery sheath is positioned in the LAA and the occluder attached to a 
delivery cable is advanced through the sheath and properly positioned in the LAA. 
Once a stable position is achieved, the delivery cable is detached from the device 
and the delivery system removed. 
 
 
Figure 3. Procedural steps 
A: transseptal puncture to gain access to the left atrium; B: depicting the LAA to exclude presence of 
thrombus and assess anatomy for device selection; C: deployment of the device in the LAA; D: Release of 
the device by unscrewing it from the delivery cable. 
 
The procedure can be done either under general anesthesia, conscious sedation, or 
with local anesthesia. The latter considerably simplifies the entire procedure but 
hardly permits procedure guidance by transesophageal echocardiography (TEE) 
without significant discomfort for the supine patient and a risk of aspiration. How-
ever, fluoroscopy guidance is sufficient and saves time and cost. 
 
Follow-up imaging needs to be done to ensure a long-term stable device position 
and sufficient exclusion of the LAA from bloodstream. It is also instrumental to rule 
out mobile thrombus on the device. Our own routine is to perform a transthoracic 
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echocardiogram before discharge, which may be the day of the procedure to ensure 
the device is still in place. At 3-6 months post-procedure a TEE is performed at 
which time the platelet inhibition therapy can be stopped if complete exclusion of 
the LAA and freedom of thrombus are documented. Patients are generally dis-
charged on vitamin K antagonists for a limited time or as at our center on acetylsal-
icylic acid and clopidogrel. Clopidrogrel is stopped after 1 month. Endocarditis 
prophylaxis is recommended for a few months until the device is assumed to be 
fully covered by endocardium.  
  
The initial but no longer available PLAATO device was a self-expanding, polytetra-
fluoroethylene (PTFE)-covered nitinol cage with stabilizing anchors. The PTFE 
covering prevented further blood flow into the LAA. The device came in diameters 
ranging from 15-32 mm. The Amplatzer Cardiac Plug (ACP) it is a nitinol mesh, 
consisting of a lobe with tiny hooks (anchors), and a sealing disc towards the left 
atrium (‘pacifier principle’). The 2 parts are connected with an extensible and flexi-
ble thin waist and filled with polyester to enhance endotheliazation and preventing 
blood flow into the LAA. It comes in sizes ranging from 16-30mm. 
 
The Watchman device is a jellyfish-like self-expandable nitinol device with barbs as 
anchors, a covering PTFE-membrane and sizes ranging from 21-33 mm. As with the 
PLAATO device, the PTFE-membrane is meant to seal the LAA entry towards the 
left atrium, preventing blood flow into the LAA. 
 
The main differences between the ACP and the Watchman device are the presence 
of an occluder disc towards the LAA in the ACP designed to facilitate complete ex-
clusion of the LAA. The Watchman device needs to be fit precisely into the LAA 
orifice in order to effectively seal off the LAA without creating too much of a cul-de-
sac while at the same time avoiding device protrusion into the left atrium. 
Bern experience with left atrial appendage closure using the Amplatzer Cardiac Plug 
Of the initial 100 patients undergoing LAA closure using the ACP and only local 
anesthesia without transesophageal guidance, the mean age was 72±10 (range 35-
92) years and the CHA2DS2-VASc Score was 3.7±1.7 (range 1-8). Indications 
stretched from repeated bleeding under vitamin K antagonists to patient prefer-
ence.  
 
We typically use the described double-curved TorqVue 13 French delivery sheath 
of St. Jude Medical (Figure 3). The delivery sheath is placed close to the LAA ostium 
and angiographic imaging is done using contrast injections through the sheath to 
exclude the presence of an LAA thrombus (usually confirming what was seen in a 
preliminary TEE) and assess the topography. The landing zone is estimated using 
the sheath’s outer diameter (5.1mm) as a reference and a device with a lobe diame-
C U R R E N T  P R O B L E M S  A N D  U N S O L V E D  I S S U E S  
 55 
ter several mm larger is selected. After ACP implantation no vitamin K antagonists 
are used. Dual antiplatelet therapy (acetylsalicylic acid and clopidogrel) is pre-
scribed for 1 month, followed by acetylsalicylic acid alone for 3-6 months, at which 
time a TEE is performed to confirm stable device position of the device, proper 
sealing of the LAA, and freedom of mobile clots. 
 
Reasons for LAA closures were history of major bleeding in 46%, high risk for 
bleeding in 25%, history of falls in 8%, labile INRs in 4%, and patient preference in 
16%. The procedure was successful in 98% of our patients. Despite the fact that 
LAA closure was often performed in conjunction with other interventional proce-
dures (coronary angiography in 65%, PFO or ASD closure in 34%, percutaneous 
coronary intervention in 25%, transcatheter aortic valve replacement in 10%, and 
atrial fibrillation ablation in 7%), the periprocedural complication rate was ac-
ceptable (6%) with no deaths, myocardial infarctions, or long-term disabilities. Two 
patients suffered pericardial effusions, whereof one required pericardiocentesis. 
Device embolization occurred twice with one device being successfully, snared and 
extracted, and reimplanted. The other embolized device made semi-elective sur-
gery necessary. Transient neurologic symptoms were discovered in two patients, 
both fully recovered on the following day. 
 
Our data demonstrate that LAA closure can be successfully performed under local 
anesthesia and without TEE. A risk for complication remains but most are minor. 
None of our patients experienced complications with long-term health impact. 
 
Patients undergoing transcatheter aortic valve replacement (TAVR) often have AF 
and a high HAS-BLED score including atherosclerosis. Some additionally receive 
coronary stents mandating antiplatelet therapy30. This engenders a high bleeding 
risk. The future will show whether such patients benefit from a combined interven-
tion (TAVR, LAA closure, and, perhaps, coronary stenting), as done in 10% of our 
cohort. 
Conclusions 
LAA closure has become an established and proven therapeutic alternative to oral 
anticoagulants for patients in atrial fibrillation. Serious complications are rare. All 
patients with an indication for anticoagulation that are for any reasons no or poor 
candidates for oral anticoagulation therapy should undergo LAA closure, provided 
no clot has formed yet in the LAA. In the remaining patients where medical therapy 
with oral anticoagulants is an option, LAA closure can be offered as an alternative 
or complementary treatment. Undergoing LAA closure means trading the life-long 
risk of bleeding complications under oral anticoagulants against an early risk for 
complications during the intervention. With the new oral anticoagulants, the long-
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term risk of serious bleeding complications will likely be reduced but the above 
balance is still valid. 
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Abstract 
 Objectives. To report a 10-year single center experience with Amplatzer devic-
es for left atrial appendage (LAA) occlusion. 
 Background. Intermediate-term outcome data following LAA occlusion is 
scarce. 
 Methods. Short and intermediate-term outcome of patients who underwent 
LAA occlusion was assessed. All procedures were performed under local anesthesia 
without transesophageal echocardiography. Patients were discharged on acetylsali-
cylic acid and clopidogrel for 1 to 6 months.  
 Results. LAA occlusion was attempted in 152patients (105males, age 72± 
10years, CHA2DS2-Vasc-score 3.4±1.7, HAS-BLED-score 2.4±1.2). Non-dedicated 
devices were used in 32patients (21%, ND group) and dedicated Amplatzer Cardiac 
Plugs were used in 120patients (79%, ACP group). A patent foramen ovale or atrial 
septal defect was used for left atrial access and closed at the end of LAA occlusion in 
40patients. The short-term safety endpoints (procedural complications, bleeds) 
occurred in 15 (9.8%) and the efficacy endpoints (death, stroke, systemic emboliza-
tion) in 0 patients. Device embolization occurred more frequently in the ND as 
compared to the ACP group (5patients or 12% vs 2patients or 2%).  
 Mean intermediate-term follow up of the study population was 32months 
(range 1-120). Late deaths occurred in 15patients (5 cardiovascular, 7 non-cardiac, 
3 unexplained). Neurologic events occurred in 2, peripheral embolism in 1, and 
major bleeding in 4patients.  
The composite efficacy and safety endpoint occurred in 7% and 12% of patients. 
 Conclusion. LAA closure may be a good alternative to oral anticoagulation. This 
hypothesis needs to be tested in a randomized clinical trial to ensure that all poten-
tial biases of this observational study are accounted for.  
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Introduction 
Percutaneous left atrial appendage (LAA) occlusion is an alternative treatment 
option to oral anticoagulation (OAC) in patients with atrial fibrillation1-7. A variety 
of dedicated and non-dedicated devices were or are currently used for LAA occlu-
sion: after the PLAATO-device3 was taken off the market due to economic reasons, 
the devices most often used were non-dedicated Amplatzer devices2, such as patent 
foramen ovale (PFO), atrial septal defect (ASD), and ventricular septal defect (VSD) 
occluders (St. Jude Medical, Plymouth, MN), the dedicated Watchman device (Ar-
tritech, Plymouth, MN)4, and since 2008 the dedicated Amplatzer Cardiac Plug 
(ACP) (St. Jude Medical, St. Paul, MN)5-7.  
 Operator experience is an important determinant for success, as LAA occlusion 
has to be considered a complex procedure8 with a considerable learning curve. 
Dedicated devices were designed and further adapted to offer better procedural 
outcome with lesser risk for device embolization.  
 In the randomized PROTECT-AF trial4, more early complications in patients 
treated with LAA occlusion were overcome by more late events in the warfarin 
group. The majority of primary safety endpoints (procedure complications, bleeds) 
in the LAA occlusion group occurred at the day of the procedure, whereas in suc-
cessfully treated patients, the 2-year safety endpoint was significantly less frequent 
in the LAA occlusion group as compared to patients on warfarin. On the other hand, 
in the per protocol analysis, the primary efficacy event rate (death, stroke, periph-
eral embolization) was twice as high in the warfarin group as compared to the LAA 
occlusion group. 
 It can thus be speculated that a mechanical solution (by means of LAA occlu-
sion) becomes more favorable over OAC the longer the follow-up. The early proce-
dural hazard is overcome by continuous late events in the control group.  
 The goal of the present study was to fill in the gap of intermediate-term out-
come data of patients that underwent LAA occlusion. Furthermore, we compared 
the outcome of dedicated versus non-dedicated devices to investigate whether 
dedicated devices in fact lead to better procedural outcome. This report is an ob-
servational study and can only be used to support the concept that occlusion of the 
LAA with the ACP device is preferable to OAC. 
Methods 
Patients 
All patients with non-valvular atrial fibrillation and an indication for long-term oral 
anticoagulation (CHA2DS2-Vasc Score of ≥1) were eligible for LAA occlusion. Indi-
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cations included a history of previous bleeding, patients at high-risk of bleeding, or 
patient preference.  
 All patients gave written informed consent before the procedure according to 
the stipulations and approval of the institutional Internal Review Board. This was a 
retrospective analysis of prospectively collected data, but not a randomized clinical 
trial. 
Non-dedicated Amplatzer devices and Amplatzer Cardiac Plug 
During the years 2002-2008, non-dedicated LAA occlusion devices were used (off-
label use of Amplatzer PFO, ASD and VSD occluders, Figure 1A). After 2008, the 
dedicated Amplatzer Cardiac Plug (ACP, Figure 1B) was utilized almost exclusively.  
 
 
Figure 1. Non-dedicated and dedicated LAA occlusion devices 
A: non-dedicated devices (from left to right): PFO, ASD, and VSD occluders. 
B: ACP. Note the hooks on the lobe for anchoring of the device. 
 
The devices are made of a nitinol mesh and polyester filling to enhance endotheli-
alization and prevent blood flow through the device. The non-dedicated devices 
consist of 2 disks with a connecting waist of variable diameter depending on the 
device chosen. The ACP is composed of a lobe with tiny hooks for device anchoring 
and a sealing disk towards the left atrium. A thin, stretchable waist connects the 
lobe and the disk. 
 The Amplatzer TorqueVue 180° delivery sheaths (for the non-dedicated devic-
es) or the dedicated Amplatzer ACP delivery sheaths were used (both by St. Jude 
Medical, Plymouth, MN). 
Procedure 
Procedures were performed in the catheterization laboratory using local anesthesia 
and fluoroscopic guidance only. LAA occlusion was performed either alone or in 
conjunction with coronary angiography, coronary angioplasty, transcatheter valve 
implantation, PFO or ASD closure, or pulmonary vein isolation.  
 At the beginning of the procedure, 5000 units of heparin were given. In case a 
PFO or ASD was present, they were used for left atrial access. Otherwise a transsep-
tal puncture was performed using an 8 French transseptal kit (MullinsTM transsep-
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tal sheath and Brockenbrough needle, Medtronic Inc., Minneapolis, MN). The obtu-
rator of this sheath accepts a stiff-shaft 0.035 inch Backup wire (Boston Scientific, 
Natick, MA, USA) used to introduce the Amplatzer delivery sheath. The LAA was 
visualized using contrast injections through this sheath in different angulations in 
order to identify the neck and the lobes of the LAA.  
 Given the known outer diameter of the delivery sheath (3.0 - 5.5 mm), the di-
ameter of the landing zone was estimated, aiming for a device with a diameter at 
least 20% oversized compared with the LAA dimension (Figure 2A). The device was 
deployed in the LAA and a stable device position was confirmed by a tug test and 
contrast injections at imaging planes perpendicular to the device in the lobe (both 
parts of the device fully separated) to ensure circumferential anchoring in the LAA. 
Since 2006 a pusher cable with a moveable core was preferentially used9, 10. It af-
forded to pull back the sleeve around the core-wire to which the screw is attached. 
This revealed the stability of the device largely uninfluenced by the attached safety 
tether. Then, the device was released (Figure 2B and C). A transthoracic echocardi-
ogram confirmed stable device position either the day of the procedure (in case the 
procedure was performed on an outpatient basis), or the following day. 
 
 
Figure 2. Device deployment 
A: Contrast injections to the LAA through he delivery sheath with a known outer diameter (double
arrow on the right: 13F ACP delivery sheath corresponding to 5.5mm). The diameter of the landing zone
is estimated and a device is chosen aiming for at least 20% oversizing. 
B: An Amplatzer ASD device (left) and an ACP device (right) are depicted. 
C: Once a stable device position is confirmed, the device is released (left: ASD device; right: ACP). 
 
Patients were discharged on acetylsalicylic acid (100mg) and clopidogrel (75mg) 
for 1 to 6 months (except for patients who underwent concomitant left atrial abla-
tion who remained on OAC for 3 months), at which time a follow-up transesopha-
geal echocardiography (TEE) was performed to confirm proper seating of the LAA 
and to look for residual leaks or thrombi on the device. In addition, a neurology 
consult was performed at the time of the TEE. 
 Procedural success was defined as a device in the LAA after 6 months irrespec-
tive of residual leaks, the time point where transesophageal echocardiography was 
performed.  
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Follow-up 
A follow-up of all patients who had attempted percutaneous LAA occlusion was 
performed in the summer of 2012. Bleeding events, neurologic events, deaths (car-
diovascular, other or unknown), current antithrombotic therapy, and hospitaliza-
tions were assessed. In case of an event, the treating family doctor or cardiologist 
were contacted, or hospital chart reviews were performed if necessary. 
Endpoints and Statistics 
Endpoints were divided into safety and efficacy endpoints. The safety endpoint was 
defined as the composite of procedure related complications (pericardial effusion, 
device embolization, and procedure related stroke) and major bleeds (according to 
TIMI Bleeding Criteria for classification of Non-CABG related bleeding). The efficacy 
endpoint was defined as the composite of cardiovascular and unexplained deaths, 
neurologic events (ischemic and hemorrhagic stroke, transient ischemic attacks), 
and systemic embolism. 
 Short-term outcome included the first six months of follow-up with subgroup 
analyses including comparison of patients treated with non-dedicated versus dedi-
cated devices. If after 6 months a device was in place (start of intermediate-term 
follow-up), no difference between non-dedicated and dedicated devices was ex-
pected. Therefore, subgroup analyses for intermediate-term follow-up (>6months) 
compared patients with a device in place versus patients with no LAA occlusion 
device. 
 Data are presented as mean and standard deviation (SD). Between groups 
comparisons were done using paired t-test for numerical, Mann-Whitney test for 
ordinal and Fishers exact test for nominal data. A p-value of ≤0.05 was considered 
statistically significant. 
Results 
Patient characteristics 
LAA occlusion was attempted in 152 patients (105 males, age 72 ± 10 years) in 
atrial fibrillation (persistent or permanent in 72, paroxysmal in 80). Mean 
CHA2DS2-Vasc score was 3.4±1.7 and mean HAS-BLED score was 2.4±1.2. Heart 
failure was present in 29 (19%), arterial hypertension in 114 (75%), diabetes 
mellitus in 35 (23%), and a history of prior stroke in 47 patients (31%). 
 Reasons for LAA occlusion were prior relevant bleeding in 38 (25%), high-risk 
of bleeding in 68 (45%), high-risk of falls or prior falls in 11 (7%), and patient pref-
erence in 37 patients (24%). 
 In 21 patients (14%), the procedure was performed on an outpatient basis. 
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Baseline characteristics are presented in Table 1. 
 
Table 1. Baseline characteristics 
Baseline characteristics in the overall population, the population treated with a non-dedicated device 
and the population treated with the ACP device. Between group comparison was done using unpaired t-
test. 
Baseline characteristics Overall population 
(n=152) 
ND group 
(n=32) 
ACP group 
(n=120) 
p-value 
Age (years) 72 ± 10 64 ± 8 74 ± 10 <0.0001 
Male 105 (69%) 23 (72%) 82 (68%) 0.83 
CHA2DS2-Vasc 3.4±1.7 2.6±1.6 3.7±1.6 0.0013 
HAS-BLED 2.4±1.2 1.7±1.1 2.6±1.2 0.0004 
Hypertension 114 (75%) 16 (50%) 98 (82%) 0.0005 
Diabetes mellitus 35 (23%) 2 (6%) 33 (28%) 0.009 
History of stroke 47 (31%) 7 (22%) 40 (33%) 0.28 
Procedural and short term outcome 
Non-dedicated devices were used in 32 patients (21%, ND group), and a PFO, ASD, 
or VSD occluder was used in 2 (6%), 20 (63%), and 6 (19%) of them, respectively. 
The dedicated ACP was used in 120 (79%) patients (ACP group). In the remaining 4 
patients prototype Amplatzer devices were used.  
 In 4 patients, 2 devices were implanted in the LAA, in 3 patients during the 
initial procedure and in 1 patient during follow-up. Reasons for implanting a second 
device were a large residual shunt or a specific LAA anatomy. Devices implanted 
were an ACP and PFO-device, 2 ACP devices and 2 PFO occluders in 1 patient each, 
and an ACP and Vascular Plug in the remaining patient. 
 LAA occlusion was performed in conjunction with coronary angiography in 105 
(69%), percutaneous coronary intervention in 29 (19%), left atrial ablation in 10 
(7%), and transcatheter aortic valve implantation in 11 patients (7%). A PFO or 
ASD was used for left atrial access and was closed at the end of the LAA closure 
procedure in 40 patients (26%). 
 
LAA occlusion was attempted in all 152 patients. Procedural complications oc-
curred in 13 patients, which consisted of neurologic events in 3, cardiac tamponade 
in 4, and device embolization in 6 patients. Short-term complications occurred in 2 
patients: 6 days after the procedure, 1 patient died of gastrointestinal bleeding that 
was the indication for LAA occlusion. At 6 months follow-up 1 device embolization 
was detected on transesophageal echocardiogram that had apparently occurred 
before hospital discharge but was missed.  
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The composite procedural and short-term safety endpoint occurred in 15 (ND 7, 
ACP 8) and the efficacy endpoint in none of the patients. Three procedural neuro-
logic events occurred (2 transient ischemic attacks and 1 minor stroke with com-
plete recovery after 3 months; ND 0, ACP 3). None of the patients had persisting 
neurologic deficits. Cardiac tamponade occurred in 4 patients (ND 2, ACP 2) and 
was treated with pericardiocentesis in 3 and emergent surgical intervention (in-
cluding surgical ligation of the LAA) in 1 patient. In 1 patient where tamponade was 
treated with pericardiocentesis, the procedure was abandoned and the patient did 
not have the LAA occluded. This was the only patient without device placement. No 
patient with procedural cardiac tamponade suffered long-term sequelae. 
 Device embolization occurred more frequently in the ND as compared to the 
ACP group (5 or 12% vs 2 or 1.6%, p=0.0048). Six embolizations occurred during 
the procedure, while 1 occurred later and was detected at routine follow-up at 6 
months. Embolized devices were snared and externalized in 3 patients and 2 un-
derwent successful implantation of another device at the same sitting. The patient 
with late detection had the device snared and removed through an inguinal cut-
down but did not receive another device. One patient had surgical removal of the 
device from the femoral artery after successful occlusion of the LAA with another 
device. Cardiac surgery with surgical ligation of the LAA was performed in 3 pa-
tients. 
 Overall, 6 patients remained without a percutaneous LAA occlusion device in 
place (3 in the ND group and 3 in the ACP group) due to embolization in 4 and car-
diac tamponade in 2. Four of the 6 patients underwent cardiac surgery and had 
surgical ligation of the LAA. Two patients did not have their LAA occluded. 
 Procedural outcomes are summarized in Table 2. 
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Table 2. Outcome of LAA occlusion: 
Short-term outcome is divided into patients treated with the ACP device versus patients treated with 
non-dedicated devices. 
Longterm outcome is divided into patients that underwent successful percutaneous LAA occlusion (pts 
w/ perc LAAO) and patients that were treated either by surgical LAA occlusion or had their LAA not 
occluded (pts w/o perc LAAO). 
LAAO related outcome comprises of events directly and causally related to LAA occlusion. 
Short-term outcome Overall population 
(n=152) 
ND group 
(n=32)  
ACP group
(n=120) 
p-value 
Neurologic events 3 (2%) 0 3 (2.5%) 0.37 
Cardiac tamponade 4 (2.6%) 2 (2.5%) 2 (1.6%) 0.15 
Device embolization 7 (4.6%) 5 (12%) 2 (1.6%) 0.0048 
Death  
- cardiovascular  
- non-cardiac 
 
0 
1 (0.6%)  
(d/t GI bleed) 
0 
0 
0 
1 (0.8%) 
 
 
0.60 
Safety endpoint 15 (9.8%) 7 (22%) 8 (6.7%) 0.0061 
Efficacy endpoint 0 0 0 N/A 
Bailout surgery 5 (3.3%)
(card. surgery in 4) 
3 (9%) 2 (1.6%) 0.063 
 
Long-term outcome Overall Pts w/o perc 
LAAO (n=6)  
Pts w/ perc 
LAAO (n=145) 
 
Cardiovascular death 5 (3.3%) 0 5 (3.4%) 0.64 
Death  
- Noncardiac  
- Unexplained  
 
7 (4.6%) 
3 (2%) 
0 
3 (50%) 
7 (4.8%) 
0 
 
0.58 
0.72 
Neurologic events 2 (1.3%) 1 (16.6%) 1 (0.7%) 0.83 
Systemic embolism 1 (0.7%) 0 1 (0.7%) 0.84 
Major bleed 4 (2.6%) 1 (16.6%) 3 (2.1%) 0.029 
Safety endpoint 4 (2.6%) 1 (17%) 3 (2%) 0.029 
Efficacy endpoint 11 (7.2%) 1 (17%) 10 (6.9%) 0.037 
 
Overall outcome
Safety endpoint 19 (12.5%)
Efficacy endpoint 11 (7.2%)
 
LAA occlusion related 
outcome 
Short-term Long-term Overall
Safety endpoint 14 (9.2%) 2 (1.3%) 16 (10.5%) 
Efficacy endpoint 0 2 (1.3%) 2 (1.3%) 
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Follow-up 
Follow-up was complete in all but 1 patient (99%). Mean intermediate-term follow 
up of the study population was 32 months (range 0.4-120 months). 
 135 patients were alive. Deaths occurred in 16 patients, of which 15 were late 
deaths (>6months after the initial procedure). Of those, 5 were cardiovascular, 7 
non-cardiovascular, and 3 unexplained deaths. The cardiovascular deaths included 
1 patient with progressive heart failure, 3 myocardial infarctions (where 2 present-
ed as sudden cardiac deaths), and 1 patient who underwent LAA occlusion and 
transcatheter aortic valve implantation at the same session and died of progressive 
heart and renal failure after 33 days.  
 Of the cohort, 15 patients (10%) were still taking OAC. The reasons for contin-
ued OAC were a history of pulmonary embolism in 2, incomplete LAA closure in 4 
and thrombus on the device in 2 patients. Two patients did not undergo percutane-
ous or surgical LAA occlusion and therefore were still on OAC. In the remaining 5 
patients (all in the ND group) there was no obvious reason why they were still on 
OAC. 
 One patient, in whom a thrombus on the device was found during routine fol-
low-up TEE refused to to take OAC. He developped a systemic embolism to his leg 
30 months after LAA occlusion which required a surgical intervention. 
 During follow-up, neurologic events occurred in 2 patients. Both were ischemic 
strokes, 1 was minor and 1 major (Rankin 4). Both patients were in the ND group, 
but 1 patient had had surgical ligation of his LAA (due to procedural embolization 
of the device). Therefore, in percutaneously treated patients only 1 neurologic 
event and 1 systemic embolism occurred.  
 Bleeding complications occurred in 13 patients (9%). Of those, 4 were major 
bleeds (2 intracerebral bleeds and 2 subdural hematoma). One of the patients with 
subdural bleeding did have a successful initial procedure with implantation of a 
small ASD occluder. On routine echocardiography after 6 months device emboliza-
tion was discovered that apparently had been missed at discharge. The device was 
found in the femoral artery and was subsequently snared and externalized. He did 
not undergo another LAA occlusion attempt and was therefore on longterm OAC. 
The second subdural hematoma occurred in a patient on acetylsalicylic acid alone 
with a mesothelioma and frequent falls. One of the intracerebral bleeds occurred in 
a patient who was on dual antiplatelet therapy for 12 months due to previous coro-
nary stenting and transcatheter aortic valve replacement. The second patient with 
an intracerebral bleed was found to have a thrombus on the ACP during follow-up 
and was subsequently put on OAC for a limited period of time during which the 
bleeding occurred. Minor bleeding occurred in 9 patients. 
 Overall, the composite efficacy and safety endpoint (intention-to-treat analysis) 
including procedural events occurred in 11 and 19 patients. Excluding short-term 
events for better appreciation of the protection provided by LAA closure, the effica-
cy and safety endpoints occurred in 11 (7.2%) and 4 (2.6%) patients, respectively.  
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Follow-up outcome is summarized in Table 2. 
 
In successfully treated patients, short-term follow-up transesophageal echocardi-
ography was performed after 3 to 6 months, and showed residual shunt into the 
LAA in 9 patients (5 or 17% in the ND group and 4 or 3% in the ACP group, 
p=0.009). Thrombus on the device was present in 14 patients (16%), which was 
treated with OAC for at least 3 months. In all 14 patients the thrombus resolved, 
except in 1 patient who refused to undergo repeat transesophageal echocardiog-
raphy. 
Discussion 
We report a single center experience over 10 years with percutaneous LAA occlu-
sion. To our knowledge, this is the longest follow-up of LAA closure reported.  
 There are 4 main findings in our study:  
 There was (1) improved short-term outcome with the dedicated ACP as com-
pared to non-dedicated devices as already shown in a retrospective pilot-study9. 
Despite the improvements, (2) safety events occur in approximately 7% of patients. 
Thus, LAA occlusion remains a technically demanding procedure. Once the proce-
dural risk is overcome, (3) intermediate-term outcome is excellent. (4) Device 
thrombus is a relatively frequent finding on routine follow-up TEE, entailing thera-
peutic consequences.  
 
Our study is different than previous studies1: Although most patients underwent 
transesophageal echocardiography during preliminary work-up, no echocardio-
graphic guidance was used during the procedure, which were performed under 
local anaesthesia only. Secondly, most patients underwent LAA occlusion in con-
junction with other interventional procedures.  
 
Since the withdrawal of the Plaato system (ev3 Inc., Plymouth, MN), the Amplatzer 
devices are the longest-used devices for LAA closure (10 years). Our data confirm 
the promising results when using these devices. We observed significantly less 
device embolizations in the ACP group, indicating that the design of the ACP and the 
special LAA sheath enhance proper anchoring in the LAA. We experienced less car-
diac tamponade, but more embolizations with the ACP as compared to previous 
studies using the Watchman device4. This finding warrants further investigation. 
Interestingly, two-thirds of the embolizations in the Watchman trial occurred dur-
ing follow-up, while in our study no late embolization occurred. This may be a mis-
interpretation of the time of events in the Watchman papers that defined the time 
of documentation of a missing device as the time of embolization. 
 
P A R T  2  
 70 
As with the ongoing continued access protocol of the Watchman device8, procedur-
al outcome in our study with the ACP compares favorably to the initial PROTECT-
AF Trial, most likely largely due to growing center and operator experience. 
 
Thrombus formation on the device remains a concern. Most patients are started on 
OAC or low-molecular weight heparin for a limited period of time11, 12. While 
thrombi typically resolve after a few months, in 1 of our patients an intracerebral 
bleed occurred during this time. This again indicates that OAC is not a benign 
treatment option in these patients. Our data further suggest, that it is indeed 
worthwhile to perform a follow-up TEE a few months after device implantation for 
exclusion of device thrombus. On the other hand, incomplete LAA occlusion seems 
not to predispose to a higher risk of stroke and therefore does not warrant further 
treatment13, 14. 
 
Our study comprised a high-risk population, as reflected by a mean CHA2DS2-Vasc-
Score of 3.4. This corresponds to an annual stroke risk of 3.5% without warfarin15. 
In a study that assessed the stroke and bleeding risk stratified according to the 
CHA2DS2-Vasc-Score in patients taking warfarin, an annual stroke risk of 1.5% and 
an annual major bleeding risk of >3% was found in patients with a comparable 
CHA2DS2-Vasc-Score as in our population16. In light of these results, the outcome 
after LAA Occlusion in our study is promising: we encountered an annual stroke 
risk of 1.2% (total of 5 events in 152 patients; average follow-up 2.6 years) and an 
annual major bleeding risk of 1% (total of 4 events in 152 patients). Of the 7 major 
complications during follow-up (2 strokes, 1 peripheral embolism and 4 major 
bleedings), 3 occurred in patients that did not have a percutaneous LAA occlusion. 
Thus, in successfully treated patients, the annual incidence of stroke and major 
bleeding was 0.8%. 
 Although this is not a randomized trial, our results of LAA occlusion compare 
favorably to treatment with OAC. Although LAA occlusion bears a certain procedur-
al risk, the longer the follow-up, the more favorable LAA occlusion becomes.  
Conclusions 
Left atrial appendage closure is a valuable alternative to oral anticoagulation. The 
benefit of the procedure increases with longer follow-up. With new dedicated de-
vices, procedural outcome was significantly improved. This observational study 
invites for a randomized trial of OAC versus the ACP for LAA occlusion to demon-
strate efficacy and safety. 
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Part 2  
Current problems and unsolved issues 
2.3. The transapical procedure 
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2.3.1. Closure of apical access site after 
transapical, transcatheter 
paravalvular leak closure 
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Abstract 
 Background. The safety of percutaneous transapical mitral paravalvular leak 
(PVL) closure could potentially be enhanced by device closure of the ventricular 
access site. 
 Methods. Percutaneous transapical PVL closure was performed. The 9 French 
delivery sheath was pulled back and a 6 mm muscular Ventricular Septal Defect 
Occluder (mVSD) was deployed at the apical puncture site.  
 Results. Immediate hemostasis was achieved. Total hospitalization was 9 days. 
NYHA functional class was improved, hemoglobin and haptoglobin rose, while LDH 
fell. Follow-up fluoroscopy and TTE revealed a good functional result. 
 Conclusion. Closure of the apical access site using an Amplatzer mVSD Occlud-
er is feasible. 
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Introduction 
The feasibility of transapical, transcatheter mitral paravalvular leak (PVL) closure 
has recently been shown1. However, bleeding complications are the Achilles heel of 
the procedure. The left ventricular apex can be accessed either through a small 
intercostal incision or by direct percutaneous puncture. While the former technique 
has potentially a lower risk of bleeding, the latter technique is a simpler and less 
traumatic approach. 
 Here we report the percutaneous device closure of the apical puncture site 
following transapical PVL closure. 
Methods 
Patient 
A 56 year-old woman with previous aortic and mitral mechanical valve replace-
ments in 1986 and redo double valve replacements in 2006 underwent On-X me-
chanical prostheses (On-X Life Technologies Inc, Austin, TX) implantation. The 
postoperative course was complicated by major bleeding requiring a re-thorac-
otomy and cardiopulmonary resuscitation. In addition, worsening symptoms of 
heart failure (NYHA class III) despite maximal medical therapy, and significant 
hemolysis in the context of a moderate mitral PVL, led to the decision to proceed 
with PVL closure. Owing to the patients high surgical risk (frailty, prior complicated 
postoperative course, renal failure, polyneuropathy, chronic immunosuppressive 
therapy), a percutaneous transapical access was decided upon, despite the lack of 
long term data supporting such an approach. 
Investigations 
Blood analysis revealed a low hemoglobin (84 g/l) and haptoglobin (<0.0583 g/l), 
and an elevated LDH (431 U/l). Transesophageal echocardiography located the leak 
on the medial aspect of the mitral valve ring with a transvalvular gradient of 
16/4mmHg (max/mean), and revealed a normal left ventricular systolic function. 
Procedure 
Following informed consent, the procedure was performed under general anaes-
thesia in a hybrid operating room (OR). It was guided by fluoroscopy, TEE and TTE.  
 PVL closure was performed as previously described1, using a direct trans-
cutaneous needle puncture of the ventricular apex. A 12 mm Amplatzer Muscular 
P A R T  2  
 78 
VSD Occluder was used. This device resulted in complete closure of the PVL (Figure 
1). The sheath was pulled back into the mid-ventricle.  
 
 
Figure 1. A: mitral leaflets fully open. B: leaflets in closed position. C: 3-D-TEE left atrial view on the 
mitral prosthesis and the Amplatzer device (*) occluding the paravalvular leak. 
 
Protamine (50mg) was given to reverse the previously administered 5000 units of 
heparine. A 6mm Muscular VSD Occluder was then advanced using the same 9 
French Amplatzer delivery sheath, and the distal disc was released into the mid-
ventricle. The sheath was subsequently pulled back into the myocardium. The sec-
ond disc was released while pulling on the sheath. After a stable device position 
was achieved and hemostasis at the puncture site was confirmed by TTE, the device 
was released.  
Results 
Procedural time was 55 min and the volume of contrast dye used was 35 ml. Repet-
itive TTE studies in the hybrid OR over the next 30 minutes confirmed hemostasis. 
The patient was extubated in the OR, transferred to the intensive care unit for 24 
hours, fully mobilized on day 3 and discharged on day 9 (NYHA class I). 
Follow-up 
Control fluoroscopy was performed on days 1, 2 and 5 and confirmed the stable 
position of the two devices. The mitral valve leaflets were freely mobile. TTE 
showed a transvalvular gradient of 11/4mmHg (max/mean), no residual paraval-
vular leak, a trivial localized pericardial effusion, and a stable position of the apical 
device (Figure 2). 
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Figure 2. Left: VSD Occluder in paravalvular position (black arrow) and VSD Occlud-
er in apical position (red arrow). Right: TTE-image showing the VSD Occluder in the 
left ventricular apex (red arrow). Note, the two discs of the apical device adjacent to 
the epi- and pericardium. 
 
The hemoglobin rose to 104 g/l, haptoglobin to 0.22 g/l, while the LDH fell to 309 
U/l. Systolic pulmonary arterial pressure fell from 76 mmHg before the interven-
tion to 33 mmHg at discharge.  
 One month following the procedure the patient was doing well and remained in 
NYHA class I heart failure. TTE revealed no residual mitral PVL, no pericardial effu-
sion and a stable position of the ventricular apical device. 
Discussion 
We described the procedural steps of ventricular apical access closure using an 
Amplatzer Muscular VSD Occluder. Only recently have a series of successful device 
closures of the apical access site using predominantly Amplatzer Duct Occluders 
been published 2. We believe that direct transapical access facilitates a variety of 
structural heart procedures and that device closure of the access site enhances the 
safety of this technique. This may be particularly pertinent in patients with friable 
myocardial tissue as in our patient. 
 Whether this technique may play a role in transapical transcatheter aortic valve 
replacement 3 merits further investigation. 
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2.3.2. Transapical Access Closure – The TA 
PLUG Device 
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Abstract 
 Objective. Percutaneous closure of the transapical access site for large calibre 
devices is an unsolved issue. We report the first experimental data of the TA PLUG 
device for true-percutaneous closure following large apical access for transcatheter 
aortic valve implantation. 
 Methods. The TA PLUG, a self-sealing full-core closure device, was implanted in 
an acute animal study in six pigs (60.2±0.7kg). All pigs received 100IU/Kg of hepa-
rin. After accessing the left ventricular apex with a 39French introducer the closure 
plug device was delivered with a 33French over-the-wire system under fluoroscop-
ic guidance into the apex. Time to full haemostasis as well as rate of bleeding was 
recorded. Self-anchoring properties were assessed by hemodynamic push stress 
under adrenalin challenge. In a foregoing feasibility study including four pigs 
(58.4±1.1kg) with full surgical exposure of the apex, device anchoring was assessed 
additionally by pull-force measurements with 0.5Newton increments. All animals 
were electively sacrified. Post-mortem analysis of the heart was performed and the 
renal embolic index assessed.  
 Results. Of 6 apical closure devices, 5 were correctly inserted and fully de-
ployed at the first attempt. One became blocked in the delivery system and was 
placed successfully at the second attempt. In all animals, complete haemostasis was 
immediate and no leak was recorded during the 5-hour observation period. Neither 
leak nor any device dislodgement was observed under haemodynamic push stress 
with repeated left ventricular peak pressure of up to 220mmHg.  
In the foregoing feasibility study assessing pull-stressing, device migration oc-
curred at a force of 3.3±0.5N corresponding to 247.5mmHg. 
Post-mortem analyses confirmed full expansion of all devices at the intended target. 
No macroscopic damage was identified at the surrounding myocardium. The renal 
embolic index was zero.  
 Conclusion. True-percutaneous left ventricular apex closure following large 
access is feasible with the self-sealing TA PLUG. The device allows for immediate 
haemostasis and a reliable anchoring in the acute animal setting. This is the first 
report of a true-percutaneous closure for large-calibre TAVI access.  
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Introduction 
Transapical transcatheter aortic valve implantation (TA TAVI) has gained wide 
popularity because of many advantages over non-antegrade access methods 1-3. The 
short and antegrade approach allows for a precise device delivery. TA TAVI is not 
being dependent on good vascular access and the wire crossing of the severely 
stenosed aortic valve is eased and directed by the native blood flow of the ejecting 
heart. No crossing of the aortic arch by the valve delivery systems is required and 
steady wire guidance is supported by wire placement in the descending aorta. The 
transapical access is not only beneficial for TAVI but it might also be the most ver-
satile access for other interventions in structural heart disease4-7and specially well 
suited to access the heart for transcatheter mitral valve repair and replacement8.  
 Despite all the very favourable evidence, the enthusiasm for the transapical 
access is hampered by the mere fact that this approach requires a surgical cut-
down and handling of the left ventricle. 
 Reliable and safe true-percutaneous entry and closure of the transapical access 
site are essential to further increase acceptance in the clinical routine. Similarly 
suture mediated and suture-less access closure has become an established routine 
for many femoral transcatheter techniques9.  
 Access closure of the apex is technically feasible. First experimental data have 
been reported and first clinical results are expected soon10. Nevertheless reported 
data do only present device based apex closure after an open surgical cut-down 
with active hooks or suture-based anchoring relying on the myocardial quality. 
 Data of true-percutaneous large calibre access closure without active hook or 
suture mediated anchoring has not been reported so far. 
 This is the first experimental study reporting successful sealing of large calibre 
transapical access with the TA PLUG device in a true-percutaneous method. 
Materials and Methods 
The sutureless TA PLUG closure device is a self-expanding and full-core device 
made from bio-compatible cellulose. Expanding from a crimped diameter of 27 
French (F) to a fully expanded diameter of 66 F the device is constructed to be self-
anchoring and self-sealing. The outer surface is lined with a porous polyeth-
ylene/polypropylene membrane. Integrated proximal and distal radio opaque 
markers define the device area to be seated in the myocardial wall. The 1.75cm long 
closure device is delivered over the wire with a 33F delivery system (Figure 1).  
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Figure 1. Over-the-wire apical closure TA PLUG loaded into the 33 French delivery
system, ready for implantation. 
Study design and Ethics 
The study was preformed in compliance with the European Convention on Animal 
Care, and with permission of the national and cantonal veterinary agency including 
permanent on-site veterinary supervision. Experiments were performed in 6 adult 
pigs (mean weight 60.2±0.7kg, range 58-62kg). The pigs were intubated and me-
chanically ventilated under general anaesthesia. A 4F pigtail catheter was inserted 
via the right carotid artery into the LV for contrast injection. Invasive haemody-
namic monitoring and blood sampling were performed through the left common 
carotid artery and a venous infusion catheter inserted into the left brachio-cephalic 
vein. Continuous ECG monitoring was recorded. All animals were electively sacri-
fied after a 5-hour observation period. 
Method 
True-percutaneous access to the apex of the left ventricle (LV) was gained under 
fluoroscopic guidance with a long biopsy needle inserted in the subxyphoid region. 
After wire exchange a 0.035inch extra stiff wire was placed in the ascending aorta. 
A cutaneous stab incision of 0.5mm was made to overcome the porcine skin re-
sistance. Intravenous heparin (100U/Kg) was administered only once before the 
procedure targeting an activated clotting time at 200s. A 39F endoscopic port ac-
cess device of 12cm length was subsequently inserted into the apex to create a 
standardized large calibre myocardial defect. 
 In a next step the 33F delivery system was advanced over the wire through the 
port access into the LV. Then the port access device was removed and the TA PLUG 
device placed into the created myocardial defect, aiming to align the apex wall with-
in the radio opaque markers. Finally the closure device was released and fully de-
ployed. After successful positioning and sealing the wire was partially pulled to 
reach the pericardial space and a modified pigtail catheter inserted into the peri-
cardium to measure bleeding. To confirm stable anchoring, throughout the obser-
vation period of 5 hours the device was visualised by repeat percutaneous contrast 
medium injection into the device and into the LV (Figure 2). Hemodynamic stress 
testing with adrenalin challenges was used to simulate increased left ventricular 
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pressure and provoke potential device dislodgement. Adrenalin administration was 
titrated to reach a systolic blood pressure of 200 to 220mmHg during at least 
2minutes. The Adrenalin challenges were repeated every 30 minutes throughout.  
 
Figure 2. Angiographic view of the deployed TA PLUG after contrast medi-
um injection into the device within the green circle. The green arrow points 
at the ventricular contrast markers of the device. 
 
In forgoing feasibility experiments including 4 pigs with surgical cut-down for apex 
exposure and access, after a two hours observation period, additionally continuous 
pull-force measurements at 0.5N increments were performed to measure pull-force 
necessary for device dislodgment. The pull-tests were not performed in the 6 pigs 
with true-percutaneous access and closure for technical reasons.  
 All animals were electively sacrified and the hearts underwent post-mortem 
analysis. The explanted specimens were prepared at the site of closure device im-
plantation and inspected for macroscopic myocardial damage or clot formation at 
the device or the surrounding tissue. 
The embolic load was assessed by means of the macroscopic embolic counts in both 
renal cortices.  
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Figure 3. Intra-operative view of the pig heart. The TA PLUG device is precisely deployed and fully
expanded within the myocardial wall of the left ventricle. 
Results 
Out of 6 true-percutaneous TA PLUG closure devices, 5 were correctly inserted and 
fully deployed at first attempt. Malfunction of the first generation delivery device 
resulted in device obstruction in the second animal. The delivery system was ex-
changed and a second device was loaded and delivered successfully at the second 
attempt. Haemostasis during the exchange of the device was achieved by temporary 
re-insertion of the 39F port access. Device success was 100%. 
 All implantations were performed without rapid pacing and all animals reached 
the 5 hours observation timeline. No major haemodynamic changes or arrhythmias 
were observed.  
 Left ventricular contrast medium injection and continuous pericardial effusion 
measurements revealed immediate sealing of the apex with complete haemostasis 
in all animals after device deployment. Because of accumulated pericardial effusion 
from exchanging the delivery system in the second animal 80ml of blood were 
drained fin this animal immediately after device insertion.  
 
No device migration was observed and all devices remained safely anchored and 
fully expanded during the 5-hour observation period despite repeated adrenalin 
challenges generating prolonged periods of systolic arterial hypertension (pres-
sures up to 220mmHg).  
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In-vivo pull-stress testing was performed in 4 additional animals with open surgical 
access to the apex. Device migration occurred at a pull force of 3.3±0.5N corre-
sponding to a left ventricular systolic pressure of 247.5mmHg. 
 All devices were firmly anchored at the intended target location and fully ex-
panded. No macroscopic damage of the myocardium surrounding the closure de-
vice was identified. Specifically neither clot formation nor haemorrhagic changes 
were identified and no pericardial effusion shown. The bilateral renal cortices 
showed zero macroscopic emboli at post-mortem.  
Discussion 
Transapical access to the aortic valve and to other intra-cardiac structures is the 
most direct and most promising route for transcatheter treatment of structural 
heart disease or even coronary heart disease11. For TAVI the transapical access 
together with the transfemoral access have become the most popular access choic-
es. Both techniques present shortcomings. 
 The transfemoral technique is generally contraindicated in patients with pe-
ripheral artery disease and has been repeatedly reported to have an important local 
complication rate12,13. Stroke rate is reported to be higher14 in transfemoral than in 
transapical access TAVI patients. Despite well-engineered delivery systems with 
increasing miniaturisation the procedure remains retrograde and as such requires 
a more challenging aortic valve crossing and generates increased shear stress in the 
aortic arch. The longer working distance from the femoral puncture site to the tar-
get area negatively affects the precision of placement and the delivery process and 
might be responsible for the significant number of patients with paravalvular re-
gurgitation15,16.  
 A stable guiding rail is missing as the guide wire can only be advanced into the 
left ventricle in a dead-end fashion and therefore cannot provide a safe and firm 
support. Further left ventricular guide wire perforations are repeatedly observed 
and reported17. Overall the transfemoral approach often represents a trade off in 
many respects including the mandatory lower crimping profile with increased 
shear forces on the device.  
 The main limitation of the transapical access are seen in the surgical cut-down 
and the direct access through the left ventricular myocardium. Creating the poten-
tial for disastrous complications. Even tough very rare reported to be below 1%18,19 
when respecting some surgical rules including access planning and identification of 
the apex as well as its myocardial thickness by CT and TEE. Careful handling of the 
purse string sutures with deep intramural stiches using Teflon felt reinforcements 
and avoiding excessive shear forces during apex handling and delivery. Wrong 
judgment, insufficient training or unexpected myocardial frailty might make the 
apex become an unnecessary formidable surgical challenge. Save and reliable de-
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vice based apex access and closure might be the essential step for further methodi-
cal adoption of transapical transcatheter techniques.  
 This study is the first experimental animal trial with the TA PLUG device to 
demonstrate that true- percutaneous transapical TAVI becomes a reproducible 
reality that will challenge other TAVI access routes in the near future.  
 
A large calibre access of 39F was repeatedly created in the left ventricle to simulate 
transapical aortic valve implantation. All percutaneous apex closures were success-
ful. All animals reached the targeted 5-hour observation period. Only in the second 
animal the closure device remained blocked in the delivery system. A second device 
was loaded and successfully implanted. After modification of the delivery system 
with a more controlled pusher-aid no system malfunction were noted in the re-
maining experiments. With exception of animal two (80ml) no measurable blood 
loss was recorded throughout. No device migration was observed despite pharma-
cologic intervention to increase intra-ventricular pressure on the device up to 
220mmHg. 
 Results from a previous not reported feasibility study including 4 animals with 
open access to the apex confirmed the present results. In the same study the devic-
es underwent pull-stress testing. Dislodgement was noted only above a pull-force of 
3.3Newtons corresponding to a left ventricular pressure equivalent of more than 
275mmHg. 
The precise deployment at the planned target location confirms the technical feasi-
bility and ease of the device setup. The absence of myocardial damage or clots indi-
cates good tissue tolerance and low risk of arterial embolism in the acute setting. 
The low thrombo-genicity of the device is also demonstrated by the absence of 
emboli in the renal cortices.  
 In contrast to previous studies10,20,21 the present closure device mechanism is 
free of any active stent like structures or anchoring hooks. The sealing is immediate 
and does not relay on haemostasis.  
 Given the feasibility character of the study, there are some limitations. The 
technical early nature of the device requires some improvements as for example a 
more precise delivery mechanism. The question of long-term bio-tolerance of the 
device core material including thrombo-genicity and inflammatory response will be 
evaluated in chronic animal experiments. 
 A true-percutaneous transapical TAVI assembles many patients’ benefits in-
cluding device durability, procedural handling and decreased complication profile 
resulting in improved overall outcomes. 
 The encouraging results of this relatively simple experimental setup indicate 
that apical closure devices are on the edge of becoming a clinical reality. Transapi-
cal TAVI may become the primary true-percutaneous access for structural heart 
disease in the coming year. This approach will challenge all other TAVI routes. 
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Current problems and unsolved issues 
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Abstract 
 Objectives. To report on the pathology of transcatheter aortic valves explanted 
at early and late time points after transcatheter aortic valve implantation (TAVI). 
 Background. Information on pathological findings following TAVI is scarce, 
particularly late after TAVI. 
 Methods. Twenty patients (13 male, median age 80 (IQR 72-84 years) with 
previous TAVI with a valve explanted at autopsy (n=17) or surgery (n=3) were 
included (10 transapical and 10 transfemoral procedures).  
 Results. Structural degeneration of transcatheter aortic valves was not seen, 
although fibrous tissue ingrowth was observed at later time points with minimal 
effects on cusp mobility in one case. Minor alterations in valve configuration or 
placement were observed in up to 50% of cases, but were not associated with sub-
stantial changes in function of the valves. Vascular or myocardial injury was com-
mon, especially within 30 days of TAVI (9/13 of cases), with the latter associated 
with left coronary ostial occlusion by calcified native aortic valve tissue in two. 
Myocardial amyloidosis was present in nearly 33%, of cases, ranged from mild to 
severe, and likely played a role in the poor outcome of 3 patients. Endocarditis, 
migration of the valve, and embolization during the procedure led to surgical valve 
removal. 
 Conclusions. Structural degeneration was not seen and minor alterations of 
valve configuration or placement did not affect valve function and were not reliably 
caused by chest compressions. Vascular or myocardial injury is very common early 
after TAVI and myocardial amyloidosis represents a relatively frequent potentially 
significant co-morbid condition. 
 
Abbreviations. 
TAVI=transcatheter aortic valve implantation 
IQR=interquartile range 
CPR=cardiopulmonary resuscitation 
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Introduction 
Transcatheter aortic valve implantation (TAVI) has been established as an effective 
treatment for patients with severe aortic valve stenosis that are either not suitable 
for open-heart surgery (1), or as an alternative treatment to open-heart surgery in 
high-risk patients (2).  
 Mortality occurring less than 30 days after TAVI reflects mostly procedure-
related mortality (3,4), while later mortality occurring from 30 days to 1year after 
TAVI is mostly caused by either progression of heart failure or the natural course of 
co-morbid conditions (5) (3,6). Procedure-related mortality decreases with in-
creasing operator and centre experience (3). Later mortality, on the other hand, 
decreases by performing the procedure in lower risk populations with less co-
morbid conditions (5).  
 Very little information is currently available on the pathological findings follow-
ing TAVI (7). Post-mortem studies in humans consist of two case reports (8,9) and a 
single series of 7 post-mortem cases (10). These prior reports primarily demon-
strate findings early after valve implantation with only one reported case with late 
follow up at 425 days (9). In this report, we describe pathologic findings in 20 
valves explanted at early, intermediate, and late time points following TAVI.  
Methods 
Patients 
All patients with prior TAVI who died and underwent a post-mortem examination 
or who had a valve surgically explanted at our institution were reviewed. Written 
permission for pathologic examination was obtained in each case. 
Valves and Procedural Approach 
The Cribier Edwards™ valve (Edwards Lifesciences, Irvine, CA), the prototypic bal-
loon-expandable prosthetic implant (11), is constructed of a stainless steel frame 
with attached equine pericardial leaflets and a fabric-sealing cuff. This was subse-
quently replaced with the Edwards SAPIEN valve with bovine pericardial leaflets 
and a longer fabric sealing cuff (12). The prosthetic valve is crimped onto a balloon 
catheter and introduced through a large sheath in the femoral artery (transarterial) 
(13) or directly through the left ventricular apex utilizing an intercostal incision 
(transapical) (14). The prosthesis is placed inside the diseased native aortic valve 
and balloon expanded displacing the native cusps.  
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Pathologic Analysis 
Entire hearts (in case of an autopsy) or the explanted transcatheter valves (in case 
of surgical removal) were fixed in 10% buffered formalin and examined by a cardi-
ovascular pathologist (MFA). Autopsy hearts were examined by a step-wise ap-
proach to identify and evaluate structural and non-structural changes in the pros-
thesis, changes associated with the prosthesis or the procedure, and other cardiac 
or vascular findings, in accordance with accepted approaches for traditional pros-
thetic valves (15) or recommendations for transcatheter valves (16). Surgically 
excised transcatheter valves were examined in a similar fashion. 
 For microscopic analysis, paraffin-embedded myocardium was section at 4μm 
and stained with hematoxylin and eosin, Masson’s trichrome (to identify fibrosis), 
Prussian blue (to identify iron), and Congo red and sulphated Alcian blue (to identi-
fy amyloid). In selected patients with relevant rhythm disturbances and/or unex-
plained death, the region of the atrioventricular node and the bundle branches 
within the interventricular septum were microscopically examined. Valve cusps, 
when examined, were sectioned as above and stained with hematoxylin and eosin, 
Movat’s pentachrome, and microbiological stains, if appropriate. 
Statistics 
Statistical analyses were done using R Statistical Computing for Mac OS. Data are 
presented as median and interquartile ranges (IQR), unless otherwise indicated. 
For each valve and cardiac findings groups (structural and non-structural chang-
es/dysfunction; prosthesis/procedure-related changes; and other cardiac changes) 
group comparison was performed using Kruskal-Willis test. Significance was taken 
at p=0.05 level for all analyses. 
Results 
Patient Characteristics 
A total of 17 valves were examined at autopsy (median age 78 years, 10 male), in-
cluding 6 Cribier-Edwards valves and 11 Edwards SAPIEN valves. Access for im-
plantation was equivalently either apical (n=9) or transarterial (n=8) for the entire 
group. Three valves were removed from patients at the time of open-heart surgery 
(median age 82 years, all males). 
Time After Implantation and Cause of Death 
Of the 17 autopsy patients, median post-procedural survival was five days (IQR 2-
25 days, range 0-943 days). Patients were stratified into three temporal categories 
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(16,17): Immediate-Early (<7 days), Intermediate (7-29 days), and Late (≥30 days). 
Death occurred in nine patients less than seven days after implantation and was 
due to cardiac causes (heart failure, major arrhythmia, rupture of adjacent struc-
tures, left main occlusion) in five, cerebrovascular accident in one, major bleeding 
in two, and sepsis in one. In the intermediate group, cause of death was cardiac in 
three and sepsis in one. After 30 days, one patient died as a consequence of an in-
tra-cerebral bleed (on warfarin for atrial fibrillation) and progressive heart and 
renal failure in three. All three surgically excised transcatheter valves were re-
moved more than 30 days after implantation, ranging from 108 to 336 days after 
implantation (Table 1). 
 
Table 1. Patient Characteristics and Pathologic Findings of autopsy cases. Sixteen cases showed some 
degree of coronary artery disease (mild – severe); 13 cases had mitral annular calcification; all 17 cases 
showed myocardial hypertrophy. 
 
Age (years) Time to death 
after implant 
Pathologic Findings Access 
Route  
Ma
le 
78 3 days Recent myocardial InjuryRecent brain injury Apical 
87 5 days Coronary ostial occlusionRecent myocardial Injury Arterial 
57 5 days Heavily calcified bicuspid aortic valveRecent brain injury Apical 
65 5 days Cuspal thrombosisRecent myocardial injury Arterial 
80 6 days Recent myocardial injuryRecent brain injury Apical 
76 2 weeks Amyloidosis Arterial 
77 28 days Possible hypertrophic cardiomyopathy  Apical 
73 1 month  Arterial 
89 20 months Fibrous tissue ingrowthAmyloidosis Arterial 
85 24 months Fibrous tissue ingrowthRecent brain injury Arterial 
 
Fe
ma
le 
84 < 1 days Vascular injuryRecent myocardial injury Apical 
58 < 1 days Vascular injuryRecent myocardial injury Apical 
81 < 1 days Partial coronary ostial occlusionRecent myocardial injury Apical 
80 5 days Recent myocardial injuryAmyloidosis  Apical 
71 10 days Recent myocardial injuryIschemic bowel Apical 
81 6 weeks Amyloidosis Apical 
99 30 months Fibrous tissue ingrowthAmyloidosis Arterial 
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Structural and Non-Structural Prosthesis Changes 
The most common structural change observed was a less than round configuration 
that ranged from slightly oval to almost D-shaped (Figure 1 and 2). This finding 
occurred across all temporal categories and, in some instances, was accompanied 
by an apparent mal-alignment or mal-apposition of valve cusps (cuspal tautness, 
laxity and/or poor coaptation). There were no macroscopic signs of cuspal degen-
eration (calcifications or cuspal tears), or any evidence of fracture or disruption of 
the metallic stent in any valve.  
 
Figure 1. Bar graph illustrating relative 
frequency of structural prosthesis chang-
es according to time after implantation. 
Expressed as %. N = 4 to 9 per group. 
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Figure 2. Non-circular configuration of a transcatheter valve re-
moved from the heart at autopsy (A) and cuspal mal-alignment 
(tautness of one cusp, arrow) in a transcatheter valve with dramatic 
alterations in configuration (B). 
 
Fibrous tissue ingrowth was found in valves from patients dying Late after TAVI 
(Figure 3) and ranged from minimal to extensive where a thin layer of filmy fibrous 
tissue covered approximately 80 to 90% of the inner aspect of the metallic stent 
(Figure 4). Localized fibrous tissue ingrowth onto the basal aspects of the cusps 
mildly reduced cuspal mobility in one case (Figure 1). 
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Figure 3. Bar graph illustrating relative frequency of non-structural 
prosthesis changes according to time after implantation. Expressed as
%. N = 4 to 9 per group. 
 
Figure 4. Photograph showing fibrous tissue ingrowth on the stent
frame of a transcatheter valve (arrow). 
 
A probe-patent paravalvular defect was another relatively frequent observation 
that spanned all temporal categories (Figure 3). Minor degrees of prosthesis mal-
position, using relation of the inferior aspect of the prosthesis stent frame to the 
insertion of the anterior leaflet of the mitral valve as a guide, were also observed in 
several cases. 
 Small amounts of recent thrombotic material on the ventricular and aortic as-
pects of the cusps (preferentially near the commissural regions) and metallic stent 
were found in one case in the Immediate-Early group. Histologically, the thrombotic 
material was comprised largely of fibrin and platelets. Notably, echocardiography 
at the time of valve implantation suggested thrombus on the guidewire and possi-
bly on the valve despite heparinization. There was no evidence of thromboembo-
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lism at the time of autopsy, however. Vegetations were not seen in any of the pros-
theses from cases examined at autopsy. 
Functional Consequences of Structural and Non-Structural Prosthesis Changes 
The majority of patients demonstrated paravalvular aortic regurgitation, as as-
sessed by echocardiography, ranging from trivial to moderate in severity. Structur-
al and non-structural prosthesis changes do not readily explain the paravalvular 
regurgitation observed. Transvalvular aortic regurgitation was not seen in the valve 
with fibrous tissue ingrowth that mildly reduced cuspal mobility. Based upon cases 
with well-documented use of chest compressions during CPR (n=8), an equal num-
ber of cases with chest compressions were found to be associated with altered 
valve shape (n=4) as compared to those that were not (n=4). However, dramatic 
changes in shape that were accompanied by tautness of one valve cusp and laxity of 
others (Figure 2b) did not demonstrate significant alterations in valve function 
during life.  
Prosthesis- or Procedure-Associated Changes 
The majority of these findings occurred primarily in Immediate-Early or Intermedi-
ate periods after implantation with a more frequent occurrence in the Immediate-
Early time frame (Figure 5) (p=0.03). Myocardial injury in the form of contraction 
band change in isolated or clusters of cardiac myocytes or areas of coagulative ne-
crosis of myocardium was observed in more than 50% of all cases with the greatest 
frequency of occurrence seen in patients dying in the Immediate-Early period (Fig-
ure 5). In select cases, acute injury of the conducting myocardium, especially the 
left bundle branch, was observed with evidence that both ischemic and direct 
traumatic injury played a role. Most likely any injuries observed arose from the 
valve or delivery system rather than the guidewire.  
 
Figure 5. Bar graph illustrating relative frequency of procedure-associated chang-
es according to time after implantation. Expressed as %. N = 4 to 9 per group. 
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Sections of healing transapical access sites showed evidence of injured myocytes, 
accumulation of mesenchymal cellular elements, haemorrhage, and small amounts 
of fibrous connective tissue deposition.  
 Apparent obstruction of coronary ostia was observed relatively frequently at 
autopsy examination providing an explanation for some of the myocardial injury 
observed (Figure 5). The most severe obstruction was observed in two cases when 
a calcified and thickened native aortic valve cusp caused complete or near complete 
obstruction of the left coronary ostium. This was accompanied by hypotension and 
showed significant ischemic myocardial injury in both. The distance from the aortic 
annulus to the left coronary ostium was relatively short in both patients: 8.5 and 
9.5mm, respectively. The left sinuses of Valsalva were of normal size and not par-
ticularly shallow. 
 Procedurally related injury to vascular or other cardiac structures were seen in 
a small number of cases (Figure 5) that when present resulted in catastrophic ef-
fects and rapidly led to very poor outcomes. Traumatic disruption of the annular 
region of the aorta occurred in one patient where the smallest available prosthesis 
(23 mm diameter) was significantly larger than the relatively small (18 mm) and 
heavily calcified annulus. In a second patient with severe mitral annular calcifica-
tion and substantially reduced leaflet mobility, a 2 cm tear involving the basal as-
pects of the anterior mitral leaflet and adjacent outflow tract (Figure 6) was created 
during the procedure that resulted in communication between the left ventricle and 
atrium and hemodynamic collapse. Transapical access was associated with massive 
bleeding followed by death due to multi-organ failure at day 5 in another patient.  
 
Figure 6. Defect (arrow) in the anterior leaflet of a mitral valve with severe
calcification of its annulus (double arrow) that led to a communication
between the left ventricle and the left atrium. 
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Other Cardiac and Vascular Findings 
All patients had evidence of increased cardiac mass or hypertrophy. Many patients 
also had coronary atherosclerosis and its manifestations including healed myocar-
dial infarction and procedures such coronary artery bypass surgery and/or percu-
taneous coronary intervention. Mitral annular calcification was also a common 
finding whose severity potentially played a role in some of the deleterious out-
comes described above. Myocardial amyloidosis was present in nearly a third of all 
autopsy cases (5 cases, ages 60 to 99 years) and ranged in severity from relatively 
mild to extensive and severe. Less severe involvement by amyloid was likely an 
incidental finding in 2 patients but where severe may have contributed to death 
due to progressive heart failure leading to death at 40, 608 and 943 days after sur-
gery. 
Findings in Surgically Excised Transcatheter Valves 
Reasons for surgical valve explantation were embolization at the time of the proce-
dure with the valve deployment in the aortic arch and definitive surgical open-
heart aortic valve replacement with explantation of the embolized valve (at day 
108), low implantation with gradual migration to the left ventricular outflow tract 
resulting in severe aortic regurgitation (at day 109), and endocarditis (at 336 days). 
In the latter case, the patient developed Streptococcus angiosus endocarditis of 
mitral and transcatheter aortic valves 6 weeks after a dental procedure that took 
place without endocarditis prophylaxis. The endocarditis spread to the mitral valve 
at the contact point of the aortic valve prosthesis with the anterior mitral leaflet 
leading to a perforation and regurgitation. 
Discussion 
As a relatively new interventional procedure, detailed pathologic examination of 
autopsy or surgical material from patients undergoing transcatheter implantation 
is critical to the on-going evolution and improvement of this approach to treatment 
of aortic valve disease. Results of the present investigation provide important in-
sights into the changes in the transcatheter valves, mechanisms and functional 
consequences of changes observed in the prostheses, emphasize key pathologies 
related to the transcatheter valve implantation procedure, and serve to highlight 
the potential significance of co-morbidities in this patient population.  
Structural and Non-Structural Prosthesis Changes 
Current surgical bioprostheses are relatively durable, although structural degener-
ation and failure can be anticipated to occur 5 to 20 years after implantation 
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(18,19) with minimal histological degeneration seen up to 6 years post implanta-
tion (20). In surgical bioprostheses, the major cause of failure is related to calcifica-
tion and tears of valve cusps, resulting in regurgitation or stenosis (21) (15). It is 
reassuring that we did not observe significant structural valve failure in any case, 
even up to 943 days after implantation. Variable degrees of fibrous tissue ingrowth 
was observed late after implantation with some localized involvement of valve 
cusps resulting in a mild reduction in cuspal mobility but had no impact on 
measureable valve function. Given its well-recognized occurrence in surgical bio-
prosthesis (15), it is highly likely that more extensive fibrous tissue ingrowth will 
occur over time in some prostheses and lead to prosthesis dysfunction, which most 
likely can be treated by valve-in-valve implantation (22).  
 A less than round configuration of the stent frame was a relatively common 
observation and the degree of non-circular configuration varied substantially. We 
cannot speculate on the reason for stent eccentricity, except for Cardiopulmonary 
resuscitation (CPR) with chest compressions as one possible explanation in pa-
tients dying after transcatheter valve implantation. However, a consistent and sig-
nificant relationship between a non-circular configuration of the stent frame and 
CPR with chest compressions was not observed. This doesn’t rule out the possibility 
that CPR with chest compressions may cause deformation in selected patients. The 
finding of deformed stent frames in this postmortem study stands in contrast to our 
finding on CT scans 3 years or more after transcatheter valve implantation, where 
circular stents were found (23). Chest compressions during CPR might explain this 
discrepancy in part but only in selected cases. Whether such deformed stent 
frames, even with mild, increase shear stress, thereby accelerate structural valve 
degeneration needs further investigation (24) (25). 
 Thrombosis and thromboembolic complications occur less often in association 
with bioprostheses as compared to mechanical valves (26). Thrombus was un-
common in our series, with significant thrombus evident in only one patient in 
whom intra-procedural heparinization may have been subtherapeutic. Neverthe-
less post-procedural thromboembolic stroke remains a concern and most groups 
utilize long term aspirin and clopidogrel for 1 to 6 months (27). The ideal an-
tithrombotic regimen is yet to be determined (28).  
 Surgical bioprostheses are said to be associated with a 4% 10-year risk for 
endocarditis (29). Mechanical valves are most often associated with localization of 
infection at the sewing ring, while infection of bioprosthetic valves is more often 
localized on the valve cusps (15). Infection of our single transcatheter valve was 
rather diffuse, involving the sewing skirt as well as the valve cusps and was accom-
panied by infection and perforation of the mitral leaflet (30). Piazza et al reported a 
similar case in a low implanted CoreValve prosthesis (31). 
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Functional Consequence of Prosthesis Changes 
Mild to moderate paravalvular aortic regurgitation after transcatheter aortic valve 
implantation is common, as was observed in patients in our study, although the 
clinical relevance of this degree of paravalvular regurgitation is uncertain (32-34). 
Despite a significantly higher incidence of trivial to moderate paravalvular leaks in 
patients after transcatheter valve implantation as compared to surgical patients, 
transcatheter valve patients have significantly better hemodynamics and improve-
ment of left ventricular function (35-37). Whether paravalvular leaks after TAVI 
result in (clinically relevant) hemolysis (as described from surgical collectives (38)) 
needs further investigation. 
 Of interest is the finding that the presence of a non-circular shape of the stent 
frame, mild degrees of mal-alignment or mal-position of the transcatheter valve, or 
presence of a probe patent paravalvular defect had no significant or consistent 
association with severity of transvalvular or paravalvular aortic regurgitation dur-
ing life. Thus, mild alterations in configuration or placement of transcatheter pros-
thetic aortic valves, as observed at autopsy, do not appear to adversely affect func-
tion.  
Prosthesis and Procedure Associated Findings 
Recent myocardial injury was a relatively frequent observation in our series of 
patients, especially in those dying in the Immediate-Early time period after implan-
tation. Left coronary ostial obstruction was likely causative in two patients and was 
associated with low origins of the left coronary artery and bulky, calcified native 
cusps in both cases (Figure 7). Another known risk factor for coronary ostial ob-
struction is a narrow aortic root with shallow aortic sinuses (39). This complication 
has been described in 0.6% of cases in a recent large registry (27), suggesting that 
multimodality screening (40) may be important. Obstruction of coronary arteries 
can be predicted during balloon valvuloplasty with aortography during balloon 
inflation. If coronary obstruction occurs during implantation, early clinical signs 
include hypotension and severe hypokinesis on echocardiography (41). Manage-
ment includes prompt cardiopulmonary support, coronary angiography, and, in 
most cases, urgent coronary revascularization (39,42,43). 
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Figure 7. Photograph showing a bulky, calcified native valve cusp filling the
sinus region of the aorta (arrow) to cause obstruction left coronary ostium. 
 
New onset of heart block can occur following transcatheter valve implantation. The 
incidence of heart block is reportedly lower with the balloon-expandable Edwards 
valve, utilized in this series, as compared to the self-expanding CoreValve (3,27,44). 
Based upon findings in select cases where the conduction system was examined, it 
appears that a combination of direct traumatic effects to the bundle branch system 
and ischemic injury occurring because of pressure-induced alterations of flow in 
coronary septal arteries in the interventricular septum are potential contributing 
factors.  
Other Cardiac and Vascular Findings 
One accompanying finding that warrants special mention is myocardial amyloido-
sis, which occurred in nearly one-third of all cases studied. Senile Systemic Amyloi-
dosis is very common in the elderly, reportedly present in 25% of individuals over 
the age of 80 years, and often goes unrecognized (45). While patients with cardiac 
amyloidosis can successfully undergo surgical procedures, operative and post-
operative problems associated with anesthesia are well described (46-48). As such, 
recognition of the possible presence of the condition and involvement of anesthe-
tists familiar with cardiac anesthesia in this setting are important. Moreover, the 
transcatheter valve approach, as compared to open-heart valvular replacement 
with cardiopulmonary bypass, may be the technique of choice in this patient popu-
lation. 
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Conclusions  
Significant structural degeneration of transcatheter valves does not occur up to 30 
months after implantation and minor alterations in valve configuration or place-
ment do not appear to be associated with substantial changes in function of the 
valves during life when assessed by echocardiography. Chest compressions during 
CPR may cause alterations in configuration of valves but only in a minority of cases. 
Myocardial injury is common early after the implantation procedure with coronary 
ostial obstruction by a thick, calcified native aortic valve cusp in the setting of a 
shallow coronary sinus, narrow aortic root, and/or low origin of the ostium likely a 
causative factor in some. Finally, myocardial amyloidosis is common in this patient 
population and warrants recognition because of its potential to have deleterious 
effects. 
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3.1. Current issues: wrap-up 
My research tried to focus on some current issues in structural interventional car-
diology. In TAVR, moving towards lower risk patients will most likely become a 
reality soon. Respective randomized trials comparing TAVR versus SAVR in inter-
mediate risk patients are currently underway (Surtavi, PARTNER 2). Irrespective of 
the results from these trials, we aim to reduce morbidity during/after TAVR. Left 
atrial appendage occlusion is an interventional approach to reduce stroke risk in 
patients suffering from atrial fibrillation, while at the same time reducing their 
bleeding risk. Long-term data are available for the Watchman device, but were 
missing for the Amplatzer occluder device. We filled this gap, showing good stroke 
prevention along with a very low bleeding rate. 
 Combining TAVR with LAAO might be an attractive treatment concept: for rea-
sons not fully understood, patients in atrial fibrillation undergoing TAVR have sig-
nificantly worse outcome as opposed to patients in sinus rhythm. 
 
As encountered in trials and in our autopsy study, potential complications during or 
after TAVR are still numerous: 
 
Table 1: 30-day incidence of complications in large clinical studies: PARTNER A 1; FRANCE 2 2; SOURCE 
registry 3 and U.K. TAVI registry 4. 
 PARTNER A FRANCE 2 SOURCE UK TAVI 
Death 3.4% 9.7% 8.5% 7.1% 
Stroke 3.8% 4.1% 2.5% 4.1% 
Vascular Complications 17% 9.7% 12.8% 6.3% 
Kidney injury 4.1% N/A 4.3% N/A 
Major Bleeding 9.3% 4,5% N/A N/A 
Pacemaker 3.8% 15,6% 7% 16.3% 
 
The most devastating complications are death and stroke. Survival after TAVR is 
not different in high-risk patients, as compared to surgical collectives. In the ‘as-
treated’ analysis of the PARTNER A 1 trial, survival was even statistically better 
after transfemoral TAVR as compared to surgery (mortality 3.7 vs 8.2%, p=0.05). 
This raises the question whether access route has an influence on survival, e.g. do 
similar patients worse is treated with a transapical approach as compared to a 
transfemoral approach. This question is hard to answer, if ‘transfemoral’ is the 
default approach and transapical is only chosen in case of concomitant peripheral 
arterial disease (selection bias). A hint to this answer comes from the SOURCE reg-
istry 3: 1-year outcome of 1038 patients (transapical: 575 patients; transfemoral 
463 patients) were reported according to the EuroSCORE. In low- (EuroSCORE 
<20), intermediate (EuroSCORE 20-40) and high-risk (EuroSCORE >40) patients, 1-
year survival was 78%, 73% and 59% in the transapical group, as compared to 
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81%, 83% and 72% in the transfemoral group. This analysis suggests that outcome 
in low-risk patients is comparable between the two access routes, whereas there is 
an advantage of a transfemoral access in intermediate and high-risk patients. This 
might be due the higher vulnerability of sicker patients to more invasive proce-
dures. With the development of smaller bore devices (e.g. the new Commander 
delivery system of the S3 valve is compatible with a 14 French sheath), the percent-
age of patients that are treated by the transfemoral route is steadily increasing.  
 Besides, with these new devices, it can be anticipated that vascular complica-
tions can be even further reduced: as shown by Toggweiler 5, introduction of 
smaller bore devices lead to a decrease in major vascular complications from 8% to 
1% and in major bleedings 14% to 1% (p>0.01). 
 
Should a patient with renal insufficiency rather undergo surgical valve replacement 
or contrast-agent dependent TAVR? We investigated this important question 6 by 
matching 119 patients with chronic kindey disease undergoing TAVR with 104 
matched patients undergoing surgical valve replacement. The incidence of acute 
kidney injury was significantly lower after TAVR as compared to surgical valve 
replacement (9.2% vs 25.9%, p<0.05). Therefore, severe kidney failure – although a 
marker of poorer longterm survival – can be a good argument to refer a patient to 
TAVR. 
 We learned that there are differences in terms of outcome and complications 
between TAVR and surgery, and that access route might play an additional role in 
this regard. But, are there differences between the two most commonly used valves 
on the market – the self-expandable CoreValve and the balloon-expandable Ed-
wards valve? According to a recent study, comparing outcomes between CoreValve 
and Edwards valves 7, there were no differences in hard endpoints: all-cause and 
cardiovascular mortality after 1 year was comparable (CoreValve 16.2% and 8.3%; 
Edwards 12.3% and 7.4%). The only significant difference was need for perma-
nent pacemaker (CoreValve 22.5%; Edwards 5.9%). From the PARTNER A 1 trial 
we know, that need for pacemaker is comparable after transcatheter Edwards valve 
implantation compared to surgical valve replacement (3.8% vs 3.6%). The vicinity 
of the intraventricular septum, the left ventricular outflow tract (LVOT) and the 
non-coronary cusp explain the mechanisms of new bundle branch blocks or atrio-
ventricular blocks. In an elaborate study, Nuis et al 8 analyzed continuous ECG’s 
during implantation of the CoreValve prosthesis. They found that conduction ab-
normalities occurred mostly during balloon valvuloplasty, followed by ‘complete 
CoreValve expansion’, again followed by ‘positioning of the CoreValve in the LVOT. 
Third degree atrio-ventricular blocks occurred in 15% of the patients, whereof two-
thirds occurred during the procedure and one-third after the valve implantation. 
 While conduction changes occur at different time-points when using a balloon-
expandable versus a self-expandable valve, the mechanisms are most likely the 
same. In our post-mortem study, we found that direct injury (e.g. by direct injury on 
the conduction system by calcified deplaced aortic valve leaflets) as well as indirect 
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injury (compression of small arteries that supply the conduction system) play a role 
in the pathophysiology (see below). While ‘you see what you get’ after implantation 
of a self-expanding valve (conduction disturbances can only recover when the ede-
ma is reduced over time), conduction disturbances can occur late (>48h) after im-
plantation of a self-expanding valve (which keeps expanding over time). Besides 
the higher need for pacemaker, the fact that severe rhythm disturbances occur late 
after CoreValve implantation poses a problem when moving towards lower risk 
patients with early discharge. Currently it is our practice to monitor all patients for 
72hours after CoreValve implantation. 
 Higher degree blocks ask for pacemaker implantation. This reliably solves the 
conduction block issue, but may lead to right-ventricular pacing, which is not well 
tolerated in some heart failure patients. Depending on the ejection-fraction, even 
biventricular pacing may therefore be indicated. 
 
In the following sub-chapters, I will delve into more detailed discussion regarding 
issues that were specifically addressed in the previous chapters: 
3.1.1.  Neurologic events 
While major strokes or the combined endpoint of death or major stroke was not 
different between the TAVR and the SAVR group in the PARTNER Trial1, more neu-
rologic events occurred (TIA, minor and major strokes) in the TAVR group after one 
year. During longer follow-up, these differences leveled out and were no longer 
statistically significant9.  
 Several arguments exist, why the two groups (SAVR and TAVR) are not compa-
rable with regard to neurologic events: patients were intubated for a longer period 
of time after SAVR. During this time period transient ischemic events or even minor 
strokes would go unrecognized. Furthermore, 30-day follow-up was held 30 days 
after randomization. Days to implant was only 10.8 days in the TAVR group, as 
compared to 15.6 days in the SAVR group – resulting in an about 25% shorter post-
procedural 30-day follow-up in the SAVR group. Another confounder is the fact that 
10% of patients randomized to SAVR did not undergo surgical valve replacement 
(as opposed to 1% in patients randomized to TAVR). Most frequent reasons were 
withdrawal of consent and refusal of SAVR in 8%.  
 When looking at the more relevant ‘as-treated analysis’, numerically more ma-
jor strokes occurred in the TAVR group (3.8% vs 2.3%, p=not significant). There-
fore, efforts to reduce the stroke rate during/after TAVR are beneficial and wel-
comed. The use of cerebral protection devices is one approach to do so.  
 In Chapter 2.1 we show that the use of the Embrella cerebral protection 
device10 is technically feasible: introduced through the right radial or brachial ar-
tery, an ‘umbrella-like’ device is introduced to the aortic arch, where a semi-
permeable mesh prevents embolization to the neck arteries, while ensuring proper 
blood flow to the protected areas. Although technically feasible, results from subse-
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quent studies are not very promising. In a contemporary review 11 on all currently 
available protection devices and the respective study results, we conclude that the 
use of protection devices can currently not be recommended: while making the 
TAVR procedure more complicated, cerebral protection devices can at best reduce 
30-day stroke rate by 50%, since the other half of the strokes occur from post-
procedural day 2 onwards. At the same time, introduction of protection devices by 
itself can potentially cause harm: latest data confirm a higher rate of silent cerebral 
lesion when the Embrella device is used, as compared to historical data without the 
use of Embrella. Mechanisms may be embolization of atherosclerotic plaques from 
the innominate artery or the aortic arch, thrombus formation or air embolism. De-
veloping smaller, less traumatic delivery catheters and increased operator experi-
ence will most likely more effectively reduce the occurrence of neurologic events 
and might even resolve ‘the stroke issue’. In my opinion, cerebral protection devic-
es will at best be used as niche products in TAVR, e.g. for selected very high-risk 
TAVR patients. We should, however, await results from large, randomized trials 
that are currently underway, before we conclusively close the books on cerebral 
protection devices. 
 
Stroke prevention is an important issue in patients suffering from atrial fibrillation 
(AF), whether or not they undergo concommittant TAVR. The CHA2DS2-Vasc Score 
is a scoring system that allows extrapolating an individual annual stroke risk. At the 
same time, the risk of bleeding in a mostly elderly patient population is substantial. 
Left atrial appendage occlusion (LAAO) is an attractive treatment option for stroke 
prevention for these patients12 13. The concept of LAAO is based on pathology data 
from AF patients, showing that >90% of all thrombi form in the left atrial append-
age. Once the left atrial appendage is occluded, the most important source of 
thrombus formation is excluded from the circulation; therefore oral anticoagulation 
can be terminated. In Chapter 2.2 we give a review of the history of LAAO, availa-
ble devices, indications and technical aspects. We further report the largest and 
longest (10 year) single center experience with Amplatzer devices for LAAO. In 
our series, stroke protection was comparable to previous reports when using oral 
anticoagulation, but at a much lower major bleeding rate. Since the procedure is 
demanding and comes along with a flat learning curve, the risk of procedural com-
plications is, however, considerable. Most of those complications are temporary 
and do not result in any long-term sequelae (e.g. tamponade, air embolism). All our 
procedures were performed in local anaesthesia and with fluoroscopic guidance 
only. This allows for a patient-friendly and efficient approach – it further allows 
performing ad-hoc LAAO (Nietlispach et al, J Interv. Cardiology, in press). After 
successful LAAO the patient’s benefit will increase the longer the follow-up. Even 
with newer, safer and more effective oral anticoagulants (rivaroxaban, apixaban 
and dabigatran), there is a higher annual rate of major bleeding complications 
(ranging from 2-3.6%/year), as compared to patients that underwent left atrial 
appendage occlusion (0.7%/year). Our data with the Amplatzer devices are sup-
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ported by recently presented long-term data from a randomized trial (PROTECT-
AF), resulting not only in significantly less strokes, but also better overall survival 
when LAAO is performed (presented by Holmes at EuroPCR 2013).  
 Given current evidence, LAAO should not only be offered to patients with pre-
vious bleeding or at high risk for bleeding, but every patient suffering AF should be 
offered the procedure as an alternative to life-long oral anticoagulation. As treating 
physicians we have to balance the risks of the two treatment strategies against each 
other: oral anticoagulation with a lifelong higher bleeding risk versus left atrial 
appendage closure that comes along with a certain procedural risk. 
 While the CHA2DS2-Vasc score is on high in the TAVR population, the same 
population is typically prone to experience major bleeding complications. Combin-
ing LAAO and TAVR is an interesting approach in the TAVR-population and might 
help to improve TAVR outcomes in these patients (see below).  
3.1.2. Pathology findings and ischemia during TAVR 
In our postmortem study 14 no valve degeneration was found in patients analyzed 
at least 20 months after the TAVR procedure (Chapter 2.4). Some fibrous tissue 
ingrowth on the stent reflects endothelialization but did not interfere with leaflet 
function. In one out of 20 valves, fibrous tissue ingrowth was extensive expanding 
to the basal part of the cusps with slight reduction in valve mobility, but not steno-
sis. The lack of valve degeneration is reassuring, but longer follow-up data will have 
to confirm this finding. Valve degeneration is of particular importance when treat-
ing lower risk populations with TAVR. Assuming durability of transcatheter valves 
of 10-15 years, a valve-in-valve procedure can be performed repeatedly if needed – 
a concept that would allow treating younger low risk patients with TAVR in the 
future. Interestingly, a less than round configuration was a common finding, leading 
in some patients to mal-alignment of valve cusps, but resulting in malfunction of the 
valve. It can be speculated that other than round configuartion can potentially lead 
to earlier valve degeneration and may also be a cause of paravalvular leakage. Car-
diopulmonary resuscitation (CPR) was performed in half of the patients with stent 
deformation – indicating that CPR can be safely performed in those patients. 
 Another finding of our postmortem study was the high prevalence of amyloido-
sis in the TAVR population. Co-existing amyloidosis could be one factor that is asso-
ciated with poor functional recovery despite valve replacement – but further re-
search is needed.  
 Damage to the conduction system is a more frequently encountered complica-
tion when using self-expanding valves. We found in patients strictly treated with a 
balloon-expandable valve, the mechanisms of new conduction disturbances to be 
either direct mechanical damage (by the valve and the displaced calcified native 
leaflets), or ischemia of the conduction cells (by mechanical obstruction of the re-
spective arteries by the valve stent). Postinterventional rhythm monitoring allows 
for timely measures, such that heart block should not cause any long-term sequelae. 
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Myocardial damage during TAVI can be due to coronary obstruction by displaced 
native valve leaflets – a complication with a high mortality rate, as we also encoun-
tered in our postmortem study. If a patient is at danger for this complication (low 
coronary-annular distance, shallow sinuses), the patient can either undergo SAVR, 
or preventive measures can be initiated prior to valve implantation (e.g. wiring the 
coronary artery and positioning of a angioplasty-balloon that once inflated would 
immediately restore coronary blood flow).  
 Direct injury from the delivery system or the guidewire is another mechanism 
causing myocardial damage. This complication occurs clinically silent in most cases. 
We found direct injury in our post-mortem study, mainly at the septum during 
transapical procedures. 
 Prolonged periods of hypotension usually occur during TAVR, either due to 
rapid pacing (for placement of self-expanding valves), relevant aortic regurgitation 
after balloon-valvuloplasty, vagal reactions or outflow obstruction during position-
ing of the prosthetic valve. These prolonged phases of hypotension could potential-
ly cause relevant ischemia in case of concommittant coronary artery disease, there-
by triggering a potentially lethal downward spiral. To avoid such complications 
during TAVR, revascularization of critical stenoses is non-controversial. However, it 
is a matter of debate whether complete revascularization of non-critical lesions 
prior to TAVR is beneficial. Data from surgical studies on aortic valve replacement 
and concomitant bypass surgery report controversial results: some showing better 
outcome when complete revascularisation is performed at the time of aortic valve 
replacement, whereas other studies cannot confirm this finding15.  
 We know that concomitant coronary artery disease is a marker of worse overall 
long-term outcome in TAVR patients. While in elderly patients one could argue that 
moderate coronary artery disease may be left alone in case the patient remains 
asymptomatic, a younger patient might benefit from complete revascularization. At 
this stage we are awaiting better data on whether complete coronary revasculariza-
tion before TAVR is beneficial or not.  
3.1.3. The transapical procedure 
We learned from the European SOURCE registry 3 that transapical (and transaortic) 
TAVR procedures might have worse outcome as compared to transfemoral TAVR, 
even after adjusting for patients’ risk. The reasons are not fully understood. Given 
the more direct access to the aortic valve, it can be speculated that rather access-
related (e.g. more invasiveness) reasons make the difference (as opposed to proce-
dure related differences). A truly percutaneous transapical access and percutane-
ous access-closure have the theoretical potential to improve outcome of transapical 
procedures. At this stage, however, no truly percutaneous apical closure system is 
available for TAVR procedures. Devices for apical closure have been investigated, 
but currently still ask for a surgical cut-down to the apex. 
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A truly percutaneous procedure through the apex with smaller bore devices is 
feasible as shown on a young but multi-morbid patient who underwent paravalvu-
lar leak closure16 (Chapter 2.3). This particular patient is doing very well three 
years after the procedure without any side effects from the apical closure device. 
The current transapical delivery sheaths are, however, more than 3-fold larger than 
the sheath used in the above mentioned patient. When thinking of using a similar, 
‘Amplatzer-like device’ for access site closure with the large bore TAVR delivery 
sheaths, new problems arise: how do you prevent invagination of the left ventricu-
lar wall when placing the sheath through the skin? Is predilatation of the puncture 
site necessary – and if yes, how can it be serially done without substantial blood 
loss while exchanging the dilators? Given the larger hole in the left ventricle, one 
can anticipate that there might be considerable leakage through the closure device. 
All the questions we currently try to address in ongoing animal experiments with a 
modified purpose-specific device.  
 Besides Amplatzer-like devices, we tested the performance of a self-
expanding, cellulose-based plug 17 (Chapter 2.3). In 6 animal experiments we 
were able to reliably close a 33F hole in the apex, without residual peri-device leak-
age. 
 
It is still a long way from promising initial results in animal studies to clinical use in 
humans, but if the concept proves to work, transapical TAVR in local anaesthesia 
may become a reality in the future. This is not only of interest for transapical TAVR, 
but the transapical access is probably the most suitable access for percutaneous 
mitral interventions. 
3.2. A glimpse into the future 
3.2.1. Combined interventions 
Atrial fibrillation is a common co-morbidity in the TAVR population, affecting about 
one third of patients and new-onset atrial fibrillation in the postprocedural period 
affects another 15% of patients. Presence of atrial fibrillation negatively affects 
long-term prognosis and is a predictor for stroke after TAVR, particularly if no anti-
coagulation regimen is initiated 18, 19. The risk of major bleeding after insertion of 
large bore devices may explain the hesitation to initiate patients on an oral antico-
agulant. Furthermore, HAS-BLED scores and CHA2DS2-Vasc scores are often high in 
this patient population, indicating a high-risk for bleeding.  
 Significant coronary artery disease increases procedural risk during TAVR. 
Addressing all patients’ issues at the same sitting is feasible: TAVR combined with 
percutaneous coronary intervention (to treat coronary artery disease) and with left 
atrial appendage occlusion (to simultaneously reduce the risk of stroke and the 
bleeding risk) resolves the aortic stenosis, treats coronary artery disease and al-
P A R T  3  
 118
lows to avoid oral anticoagulation despite the presence of atrial fibrillation. It offers 
a patient- and resource friendly solution (see figure below). Despite the theoretical-
ly higher overall procedural risk when combining these procedures, we could show 
safety of such an approach, with similar in-hospital and short-term (30-day) out-
come as compared to ‘TAVR alone’ in a preliminary analysis of 10 combined inter-
ventions (Nietlispach, presented at TVT 2013, Vancouver). With longer follow-up, 
patients undergoing combined interventions will profit more and more from a 
more complete treatment approach. Prospective data comparing a combined ap-
proach with a staged approach will be needed in the future. 
 
One-stop shopping: simultaneous PCI, TAVR, LAAO and PFO-closure during a 
single sitting 
3.2.2. Ad-hoc TAVR: the future starts now 
Pre-requisites for ad-hoc TAVR are (1) reliable fluoroscopic imaging (e.g. annular 
sizing, assessing peripheral arterial diameter) without the need of adjunctive imag-
ing, (2) reliable percutaneous peripheral arterial closure, (3) fluoroscopic guidance 
of the procedure, (4) no need for anaesthesia. 
 With smaller delivery systems, the ability to perform TAVR in local anaesthesia 
without transesophageal echocardiographic guidance 20, reliable fully percutaneous 
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arterial closure (with suture based closure devices) and with the possibility to per-
form reliable balloon sizing of the aortic annulus 21, ad-hoc TAVR has become a 
reality. New fully recapture- and repositionable valves that will become available 
shortly will further facilitate such an approach. Respective live-cases were recorded 
and presented by our group in June 2013 (C3 meeting Orlando, Florida, Operators 
F. Nietlispach and B. Meier; http://speakerready.com/C3_2013/coronary/june-20-
2013). Avoiding anaesthesia during the procedure and avoiding costly and time-
consuming investigations during the ‘work-up period’, offers a frugal, patient- and 
resource-friendly treatment.  
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Chapter 1 
Transcatheter aortic valve replacement (TAVR) is a rather young technique. In the 
first chapter, a historical overview, an overview of different access routes and the 
clinical role of TAVR are given.  
 It all started with a prototype transcatheter valve being successfully implanted 
in a pig. It was a balloon-expandable stent with a valve sutured in. Ten years later, 
Cribier performed the first successful transcatheter valve implantation in a human. 
Techniques, valves and delivery systems evolved considerably ever since the first-
in-human case, making TAVR a procedure with good and reproducible outcomes. 
Initial TAVR patients were deemed inoperable, while later TAVR was performed in 
high-risk patients. Both populations were investigated in the first large randomized 
PARTNER trials: while TAVR significantly improved survival and also reduced 
symptoms as compared to medical therapy, TAVR proofed to be non-inferior as 
compared to surgical valve replacement (SAVR). 
 While transfemoral was the initial access route, peripheral arterial disease 
precludes transfemoral TAVR in some patients, in which case a transapical, trans-
aortic or subclavian access can be chosen. 
 At the end of the chapter, current challenges are discussed which will be 
touched upon in the following chapters:  
• In the PARTNER trial, a trend towards a higher rate of neurologic complica-
tions in the TAVR arm as compared to patients treated with SAVR was seen 
(Chapter 2.1). 
• Of particular concern is the large subgroup of TAVR-patients suffering from 
atrial fibrillation: worse overall outcome and a higher stroke rate were seen in 
these patients as compared to patients in sinus rhythm. This is of particular con-
cern, since about 30-40% of TAVR patients suffer from atrial fibrillation. Left 
atrial appendage occlusion has the potential to improve the outcomes in this 
subgroup of patients. (Chapter 2.2). 
• Transapical TAVR seems to come along with worse overall outcomes as com-
pared to patients treated with transfemoral access. Decreasing the invasiveness 
of the procedure by means of a true percutaneous approach with percutaneous 
apical closure may improve outcomes in patients who undergo transapical 
TAVR (Chapter 2.3). 
• Procedural complications (e.g. left main obstruction) and long-term perfor-
mance of the valve need to be better understood. Autopsy data and pathology 
analyses from explanted valves provide valuable information (Chapter 2.4). 
Chapter 2.1 
In this chapter the stroke issue is discussed: 
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Several embolic protection devices were designed aiming at deflecting or capturing 
embolic debris during TAVR, by protecting the neck vessels. Several issues arise 
when temporarily implanting such devices during TAVR: (1) the device should 
enable sufficient blood flow to the neck vessels, (2) introduction of the device is 
supposed to be easy and fast in order not to considerably prolong the overall pro-
cedure time, (3) introduction of the device should not cause any harm, e.g. arterial 
dissection or cerebral embolization. 
 In the first section the first-in-human experience with the first available embol-
ic protection device (Embrella Embolic Deflector, year 2010) is described: An um-
brella-like device made out of a porous membrane is introduced via the radial or 
brachial artery, is deployed and is sitting at the outer curvature of the aortic arch 
where it deflects emboli away from the neck vessels. During the aortic valve inter-
vention the device is sitting in place and is removed only once the TAVR procedure 
is terminated. In this feasibility study the device was implanted in four patients, 
three of them undergoing TAVR and one undergoing aortic balloon valvuloplasty. 
Radial access was used in all and no procedural complications occurred. No pres-
sure difference was noted up- and downstream the device, indicating sufficient 
blood flow through the porous membranes. On a post-procedural cranial magnetic 
resonance imaging study, however, one new, clinically silent cortical infarct was 
noted. In conclusion we could show technical feasibility of the use of the Embrella 
device, with no interference of the device with the TAVR delivery system, no visible 
damage to the device after removal and sufficient blood-perfusion of the neck ves-
sels. Additional median procedure time was 13minutes from device insertion to 
removal. Given the low patient number, the study, does of course only allow a 
statement regarding feasibility, but not safety and efficacy of the device use. 
 In the second section, a current (year 2013) review of the pathogenesis of 
stroke during/after TAVR and of all currently available protection devices is given. 
Only half of the strokes occur during the TAVR procedure, while the other half oc-
curs later in the course. Intraprocedural strokes are caused by embolization of 
mostly aortic valve and aortic wall debris. Despite the theoretical advantage when 
using cerebral protection devices, these devices themselves carry a risk of causing 
strokes by interfering with the aortic wall and/or the carotid arteries. 4 devices are 
currently on the market, whereof two deflect emboli away from the neck vessels, 
while two capture embolic material. These four devices are reviewed and the cur-
rent evidence is summarized. One device is the Embrella device, a deflection device. 
A randomized study found new lesions on cerebral DW-MRI in all patients when 
the device was used, however, the volume of the lesions was overall smaller as 
comapred to patients where no device was used. A reduction in lesion volume 
without reduction in the numbers of lesions was also found for the second deflec-
tion device, the TriGuard. No data on cerebral embolism exists for the third device, 
the Montage Dual Filter device. A niche product is the second capture device, the 
Embol-X filter, which is sitting in the ascending aorta and can only be used for 
transaortic TAVR – no data on the efficacy of this device during TAVR procedures 
S U M M A R Y  
 125
exist. The review article concludes, that at the current stage, not sufficient data exist 
that would justify the use of these protection devices. 
Chapter 2.2 
In this chapter stroke prevention by means of left atrial appendage occlusion 
(LAAO) is discussed: 
 In the first section a review article including original data is presented. The 
increased risk of stroke in patients suffering from atrial fibrillation is discussed, 
followed by a section discussing the pros and cons of the available medical thera-
pies (oral anticoagulants). Although these medical therapies effectively reduce the 
stroke risk, the main drawback is the increased risk of bleeding. The rate of major 
bleeding with the newer and safer factor X and thrombin inhibitors are still in the 
range of 3-14%/year. Since in atrial fibrillation, the majority of thrombi arise from 
the left atrial appendage, left atrial appendage occlusion (LAAO) is an attractive 
treatment to reduce the stroke risk without a risk of increased bleeding. The price 
for this advantage is procedural complications during LAAO, such as serious peri-
cardial effusions (in about 2%), device embolization or atrial perforation. Former 
and current devices are reviewed together with implantation techniques and fol-
low-up care. At the Bern University Hospital the procedures were done in local 
anaesthesia and without transesophageal echocardiography guidance. Despite the 
fact that most LAAOs were performed in conjunction with other procedures (e.g. 
PFO closure, percutaneous coronary intervention), complication rate was accepta-
ble (6%) in the first 100 patients. No deaths or long-term disabilities occurred. The 
section concludes that LAAO has become an established therapy as an alternative to 
oral anticoagulation. 
 In the second section, the largest single-center experience with the longest 
follow-up (10-years, mean 32months) of LAAO is presented. In 152 patients LAAO 
was attempted with non-dedicated (32 patients; PFO-, VSD- and ASD-occluders) 
and dedicated (120 patients; Amplatzer Cardiac Plug) Amplatzer devices. While 
device-embolization was an issue with non-dedicated devices (occurring in 12%), 
the incidence could be considerably reduced with the dedicated Amplatzer Cardiac 
Plug (incidence 2%). During follow-up, embolic events occurred in three and major 
bleeding events in four patients. Reasons for LAAO were in order of their frequen-
cy: high-risk of bleeding, relevant previous bleeding, and patients’ preference or 
high-risk of falls. The data show that with the new, dedicated devices, outcome 
could be considerably improved and that with these devices LAAO has become a 
valuable alternative to oral anticoagulation. 
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Chapter 2.3 
In this chapter the transapical access is discussed with a focus on percutaneous 
transapical access closure. If true percutaneous transpical access with percutane-
ous apical closure became a reality, the invasiveness of the transapical approach 
could be considerably reduced and outcomes potentially improved. 
 In the first section, a case of true percutaneous access and percutaneous closure 
is described. A 56-year old patient suffered from a severe paravalvular leak after 
repeated double-valve replacement. Percutaneous apical puncture was followed by 
introduction of a 9 French sheath, over which paravalvular leak closure was suc-
cessfully performed. The novelty of the described technique was removal of the 9 
French sheath and deployment of a 6mm muscular VSD occluder at the apical entry 
site. Immediate and complete hemostasis was achieved and during follow-up the 
patient is doing well. 
 While this technique worked nicely for removal of a 9 French sheath, removal 
of larger bore devices (e.g. sheaths for transapical TAVR) may require different 
devices. Such a prototype device is described in the next section: in 6 acute pigs a 
39 French hole in the porcine apex was completely sealed by a cellulose-based plug 
(device success 100%). Repetitive contrast injections to the left ventricle and 
through the delivery sheath confirmed the stable position and stress testing (by 
adrenalin challenges to raise the left ventricular pressure >200mmHg) showed no 
device dislodgment. In another four pigs, a surgical cut-down was performed after 
device deployment and pull- and push forces were applied to document the force 
necessary to dislodge the device. Device dislodgment was found at forces corre-
sponding to pressures of 247mmHg. This study shows feasibility of closing even 
large bore holes in the apex. It paves the way for further research in this field. 
Chapter 2.4 
As compared to surgical aortic valve replacement, TAVR is still a relatively young 
technique and only small case series of autopsy results have been published. The 
next section describes the postmortem findings of a larger series of patients under-
going TAVR. Autopsy was performed in 17 patients, while three valves were re-
moved from patients at the time of open-heart surgery. Of the 17 patients, 9 died 
within 7 days after TAVR, 4 died from days 7-30, while 4 died after 30 days and up 
to 30 months. Three valves were surgically removed after 108-336 days. 
 A frequent finding across all temporal categories was a less than round configu-
ration of the valve, without any signs of enhanced valve degeneration. The same 
was true for dramatic changes in valve and stent deformation in a few specimens 
after chest compressions during resuscitation. Probe-patent paravalvular defects 
were commonly found, but did not correspond with the severity of paravalvular 
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regurgitation during life. The same was true for other than round stent configura-
tions or mild mal-alignments of valve-stents. Fibrous tissue ingrowth was found 
late after TAVR, ranging from minimal to extensive, but with interference with 
valve cusp mobility in only one single specimen. Another interesting finding was 
injury to the conduction system with evidence of direct traumatic injury (e.g. by the 
stent or calcified valve tissue) and ischemic injury (e.g. by stent compression of 
small septal arteries supplying the conduction system). Left main obstruction oc-
curred in two patients, both with a short distance of the left main ostium to the 
annulus, despite normal sizes of their sinuses of Valsalva. In one patient with a 
small and heavily calcified annulus, an annular tear created a communication from 
the left ventricular outflow tract to the left atrium, also tearing the anterior mitral 
leaflet – this event was followed by hemodynamic collapse and death. In a third of 
all patients the presence of myocardial amyloidosis was noted and could have po-
tentially contributed to progressive heart failure leading to death in three patients 
(after 40-943 days after TAVR).  
 Longer follow-up of valves may be necessary to determine the clinical signifi-
cance of fibrous tissue ingrowth, which may potentially lead to valve degeneration 
over time. If such occurs, a repeat transcatheter procedure (valve-in-valve) could 
solve the problem. 
Chapter 3 
In this chapter, the issues of vascular complications, kidney injury and pacemaker 
implantation are discussed, followed by a more focused discussion on the most 
devastating complication after TAVR: stroke. Although initial analyses of the 
PARTNER trials documented more early neurologic events with TAVR as compared 
to surgery, the incidence leveled out over time. Methods to reduce the stroke rate 
after TAVR are welcomed. Cerebral protection devices are in my opinion not suited 
for this purpose and will not solve the problem. This is due to the preliminary find-
ings on cerebral protection devices: equally many or even more ischemic lesions 
occurred when these devices were used, indicating that placement of the devices 
itself carries a certain risk. Furthermore, only 50% of strokes occur intra-
procedurally. There are more promising methods to reduce the rate of neurologic 
events: (1) reducing the size of the valve delivery systems will make the systems 
less traumatic, and (2) in patients suffering from atrial fibrillation the combination 
of left atrial appendage occlusion with TAVR is a promising way to hopefully reduce 
the stroke rate in this high-risk population. The subgroup of TAVR patients suffer-
ing from atrial fibrillation is not only exposed to a high thromboembolic risk, but 
also to a high-risk of suffering from major bleeding complications (if oral anticoagu-
lation is prescribed). Left atrial appendage occlusion can reduce the stroke rate at 
least as effectively as oral anticoagulation, but at a significantly lower bleeding risk. 
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Then the findings of the postmortem study are discussed. Durability of the 
transcatheter valves is an important issue. Even if valve degeneration occurs over 
time (and it will occur), the possibility of a repeat transcatheter valve-in-valve pro-
cedure still allows treating younger and lower risk patients with this new tech-
nique. Myocardial damage can occur acutely by displacement of the native valve 
leaflets, thereby obstruction a coronary ostium. Further, in case of coronary artery 
disease, even non-critical stenoses could lead to ischemia during prolonged periods 
of hypotension (e.g. during rapid pacing). It is still a matter of debate, if non-critical 
stenoses should be revascularized prior to TAVR. 
 An apical closure device that would enable a true percutaneous apical access 
(maybe even in local anaesthesia) may be less important for TAVR in the future, 
given the current technical developments enabling a transfemoral approach in 
more and more patients (with the most recent transfemoral delivery system requir-
ing only a 14 French sheath). However, there are patients where a transfemoral 
access is not possible due to severe peripheral arterial disease. Also, percutaneous 
devices for mitral valve replacement are underway and may lead to a renaissance 
of the transapical access. By reducing the invasiveness of this access route, out-
comes could potentially be improved in the future. 
 The final paragraph of this chapter focuses on the imminent clinical develop-
ments of the TAVR procedure: in my opinion, combining procedures (e.g. percuta-
neous coronary revascularisation, left atrial appendage occlusion and TAVR) is 
patient- and are resource-friendly and should be performed more often. I hope that 
in the near future ad-hoc TAVR will become a reality. Ad-hoc TAVR with combined 
procedures describes my vision on how TAVR should be performed in the near 
future. 
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Hoofdstuk 1 
Transcatheter aortaklepimplantatie (TAVI) is een relatief jonge techniek. In het 
eerste hoofdstuk worden een historisch overzicht, een overzicht van de verschil-
lende toegangsroutes en de klinische rol van TAVI gegeven. 
 De ontwikkeling van TAVI is begonnen met het implanteren van een prototype 
transcatheterklep die succesvol is geïmplanteerd in een varken. Dit prototype be-
stond uit een klep die gehecht was in een stent, die met een ballon geplaatst kon 
worden. Tien jaar later was Cribier de eerste die succesvol een transcatheter klep-
implantatie uitvoerde bij de mens. De techniek, kleppen en implantatiesystemen 
zijn sterk verbeterd sinds de eerste plaatsing, waardoor TAVI nu een procedure is 
met goede en reproduceerbare uitkomsten. Initieel werd TAVI gebruikt voor pati-
enten die inoperabel verklaard waren, later werden daar hoog-risicopatiënten aan 
toegevoegd. Beide populaties zijn onderzocht in de eerste, grote, gerandomiseerde 
PARTNER-trials. TAVI verbeterde de overleving en zorgde voor symptoomreductie 
ten opzichte van medicamenteuze therapie, waarbij bewezen werd dat TAVI non-
inferieur was aan chirurgische klepvervanging. 
 Als eerste keuze wordt voor een transfemorale toegangsweg gekozen, maar bij 
patiënten waarbij dat niet mogelijk is, kan gekozen worden voor transapicale, 
transaortale of transsubclaviale toegang. 
 Aan het einde van dit hoofdstuk worden de huidige uitdagingen besproken, 
waar verder op ingegaan zal worden in de volgende hoofdstukken: 
• In de PARTNER-trial is er een trend richting meer neurologische complicaties 
in de TAVI-arm gevonden, vergeleken met chirurgische klepvervanging (Hoofd-
stuk 2.1). 
• Speciale aandacht verdient de subgroep van TAVI-patiënten die lijden aan atri-
umfibrilleren: zij hebben een slechter resultaat en hogere kans op cerebrovas-
culaire accidenten vergeleken met patiënten in sinusritme. Dit is des te meer 
van belang omdat 30-40% van de TAVI-patiënten lijdt aan atriumfibrilleren. Af-
sluiting van het linker hartoor kan mogelijk het resultaat in deze subgroep van 
patiënten verbeteren (Hoofdstuk 2.2). 
• Transapicale TAVI lijkt slechtere uitkomsten te geven vergeleken met een trans-
femorale benadering. Door de transapicale TAVI minder invasief te maken door 
een volledig percutane benadering met percutane apicale sluiting, kunnen 
mogelijk de uitkomsten verbeterd worden (Hoofdstuk 2.3).  
• Er is meer informatie nodig over procedurele complicaties (zoals hoofdstamaf-
sluiting) en het functioneren van de klep op lange termijn. Data verkregen na 
obductie en pathologisch onderzoek van geëxplanteerde kleppen leveren 
waardevolle informatie (Hoofdstuk 2.4). 
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Hoofdstuk 2.1 
In dit hoofdstuk wordt gesproken over cerebrovasculaire accidenten (CVA). 
 Er zijn verschillende devices ontwikkeld om tijdens TAVI embolisch débris af te 
buigen of af te vangen door de halsvaten te beschermen. Er zijn diverse overwegin-
gen waar rekening mee gehouden moet worden bij het implanteren van dergelijke 
devices tijdens TAVI: (1) er moet voldoende bloeddoorstroming mogelijk blijven 
door de halsvaten, (2) het device moet gemakkelijk en snel in te brengen zijn om de 
procedurele tijd niet te veel te verlengen en (3) het device moet geen schade aan-
richten, met name geen arteriële dissectie of cerebrale embolisatie.  
 In het eerste gedeelte wordt de eerste ervaring in de mens met het eerste be-
schikbare device dat beschermt tegen embolisatie beschreven (Embrella Embolic 
Deflector, jaar 2010). Dit is een op een paraplu gelijkend device dat gemaakt wordt 
van een poreus membraan en dat wordt ingebracht via de arteria radialis of brachi-
alis. Het wordt ontvouwen en steunt tegen de bocht van de aortaboog, waar het 
embolieën wegvoert van de halsvaten. Het device blijft in situ gedurende de gehele 
TAVI-procedure en wordt na afloop verwijderd. In dit haalbaarheidsonderzoek is 
het device geïmplanteerd in vier patiënten, drie patiënten ondergingen TAVI en één 
een ballondilatatie van de aortaklep. Toegang via de arteria radialis werd gebruikt 
in alle patiënten en er traden geen complicaties op. Er was geen drukverschil vóór 
en na het device, wat aangeeft dat voldoende bloedstroom door het poreuze mem-
braan mogelijk was. Op een post-procedurele MRI van de hersenen bleek er bij één 
patiënt een klinisch niet opgemerkt corticaal infarct aanwezig te zijn. Concluderend 
konden wij de haalbaarheid van het gebruik van het Embrella-device aantonen, 
waarbij er geen interferentie was met het gebruik van het TAVI-systeem, geen 
zichtbare schade aan het device na afloop en voldoende perfusie van de halsvaten. 
Additionele proceduretijd was 13 minuten van insertie tot verwijdering van het 
device. Gezien het kleine aantal patiënten in de studie kunnen er uit deze studie 
alleen conclusies getrokken worden aangaande haalbaarheid, en niet over veilig-
heid of effectiviteit van het device. 
 In het tweede gedeelte wordt een overzicht gegeven van de huidige stand van 
zaken (jaar 2013) betreffende pathogenese van CVA gedurende en na TAVI met alle 
beschikbare beschermingsdevices. Niet meer dan de helft van de CVA’s vindt plaats 
gedurende de TAVI, de rest erna. Intraprocedurele CVA’s worden meestal veroor-
zaakt door embolisatie van de aortaklep en débris uit de aortawand. Hoewel de 
cerebrale beschermingsdevices een theoretisch voordeel bieden, leiden deze devi-
ces ook tot een risico op CVA’s door manipulatie van de aortawand en/of de halsar-
teriën. Er zijn op dit moment vier devices op de markt, waarvan er twee embolieën 
afbuigen van de halsvaten en twee devices het embolische materiaal afvangen. Deze 
vier devices worden besproken en het beschikbare bewijs wordt samengevat. Een 
van deze devices is het Embrella-device. Een gerandomiseerde studie toonde nieu-
we laesies op cerebrale MRI in alle patiënten waarbij het device gebruikt werd, 
hoewel het volume van de laesies kleiner was dan die van patiënten waarbij geen 
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device werd gebruikt. Een reductie in het volume van de laesies zonder reductie in 
het aantal laesies werd ook gevonden voor het tweede device dat embolieën af-
buigt, de TriGuard. Er is geen data beschikbaar over cerebrale embolieën voor het 
derde device, het Montage Dual Filter-device. Een nicheproduct is het tweede devi-
ce dat embolieën afvangt, het Embol-X filter, dat geplaatst wordt in de aorta ascen-
dens en alleen gebruikt kan worden voor transaortale TAVI – er is geen data be-
schikbaar over de effectiviteit van dit device gedurende TAVI-procedures. Het over-
zichtsartikel concludeert dat er op dit moment niet voldoende data beschikbaar is 
om het gebruik van deze devices te rechtvaardigen. 
Hoofdstuk 2.2 
In dit hoofdstuk wordt preventie van CVA door afsluiting van het linker hartoor 
(LAAO) besproken. 
 In het eerste gedeelte wordt een overzichtsartikel, inclusief originele data, ge-
presenteerd. Het toegenomen risico op CVA in patiënten met atriumfibrilleren 
wordt besproken, gevolgd door een gedeelte waar de voor- en nadelen van de be-
schikbare medicamenteuze therapieën besproken worden (orale anticoagulantia). 
Hoewel deze medicamenteuze therapieën effectief het risico op ischemisch CVA 
verlagen, leiden ze tegelijkertijd tot een verhoogd risico op bloedingen. Bij het ge-
bruik van de nieuwere en veiligere factor X- en thrombine-inhibitoren ligt het risico 
op belangrijke bloedingen nog steeds op 3 – 14%/jaar. Omdat in atriumfibrilleren 
de meeste embolieën ontstaan in het linker hartoor, is afsluiting hiervan (LAAO) 
een aantrekkelijke behandeling om het risico op CVA te verminderen zonder de 
verhoogde kans op bloedingen. De prijs die hiervoor betaald moet worden zijn de 
intraprocedurele complicaties gedurende LAAO, zoals ernstige pericardeffusie (in 
2%) en embolisatie of perforatie van het atrium. Er wordt een overzicht gegeven 
van oudere en huidige devices voor LAAO, tezamen met implantatietechnieken en 
nazorg. In het universitaire ziekenhuis van Bern werd de procedure uitgevoerd 
onder lokale anesthesie en zonder transoesofageale echogeleiding. Hoewel de 
LAAO-procedure vaak tegelijk gedaan werd met andere ingrepen (PFO-sluiting, 
percutane coronaire interventie), was het aantal complicaties acceptabel (6%) in de 
eerste 100 patiënten. Er waren geen sterfgevallen of gevallen van langdurige be-
perkingen. Dit gedeelte concludeert dat LAAO een gevestigde therapie geworden is 
als een alternatief voor orale anticoagulantia. 
 In het tweede gedeelte wordt de grootste patiëntengroep die LAAO heeft on-
dergaan gepresenteerd die in één centrum behandeld is, met de langst bekende 
follow-up (10 jaar, gemiddeld 32 maanden). In 152 patiënten werd LAAO uitge-
voerd, met niet-specifieke devices (32 patiënten; PFO-, VSD- en ASD-occluders) en 
specifieke devices (120 patiënten; Amplatzer Cardiac Plug). Hoewel device-
embolisatie een probleem was in niet-specifieke devices (12% van de gevallen), 
werd de incidentie hiervan sterk gereduceerd door het gebruik van de Amplatzer 
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Cardiac Plug (incidentie 2%). Gedurende follow-up waren er trombo-embolische 
events in 3 patiënten en belangrijke bloedingen in vier patiënten. De indicatie voor 
LAAO was, in volgorde van frequentie: hoog bloedingsrisico, belangrijke bloeding in 
de voorgeschiedenis, patiëntenvoorkeur of een hoog valrisico. De data laten zien 
dat met de nieuwe, specifieke devices de uitkomsten duidelijk verbeterd zijn en dat 
met deze devices LAAO een waardevol alternatief is voor orale anticoagulantia.  
Hoofdstuk 2.3 
In dit hoofdstuk wordt de transapicale toegang besproken, met de focus op percu-
tane sluiting van de transapicale toegang. Als volledig percutane transapicale toe-
gang met percutane sluiting hiervan realiteit zou worden, zou de transapicale toe-
gang veel minder invasief zijn en de uitkomsten hiervan mogelijk verbeterd kunnen 
worden. 
 In het eerste gedeelte wordt een casus van volledig percutane toegang met 
percutane sluiting beschreven. Een 56-jarige patiënt leed aan ernstige paravalvulai-
re lekkage na herhaalde dubbele klepvervanging. Na percutane apicale punctie 
werd een 9 French sheath ingebracht, waarover sluiting van het paravalvulaire lek 
succesvol werd uitgevoerd. De noviteit van de beschreven techniek bestond uit het 
verwijderen van de 9 French sheath en het inbrengen van een 6mm musculair VSD-
occluder op de plaats van de apicale toegang. Onmiddellijke en volledige hemostase 
werd bereikt en het gaat goed met de patiënt gedurende follow-up. 
 Hoewel deze techniek goed werkt na verwijdering van een 9 French sheath, 
vereist verwijdering van grotere devices (zoals sheaths voor transapicale TAVI) 
mogelijk een ander device. Een prototype hiervan wordt beschreven in het volgen-
de gedeelte: in 6 varkens werd een 39 French opening in het apicale gedeelte van 
het varkenshart gesloten met een cellulose-plug (succespercentage 100%). Her-
haaldelijke contrastinjecties in het linkerventrikel en door de sheath bevestigden 
de stabiele positie van de plug en stress tests (adrenaline-injecties om de linkerven-
trikeldruk te verhogen tot >200mmHg) toonden geen dislocatie van het device. In 
vier andere varkens werd na chirurgische excisie gekeken hoeveel duw- en trek-
kracht nodig was om het device te dislokeren. Dislocatie van de device werd gevon-
den bij het toedienen van krachten die passen bij drukken van 247mmHg. Deze 
studie toont de haalbaarheid van het sluiten van zelfs grotere gaten in de apex. Het 
opent mogelijkheden voor verder onderzoek in dit veld. 
Hoofdstuk 2.4 
Vergeleken met chirurgische aortaklepvervanging is TAVI nog een relatief jonge 
techniek en alleen kleine series van obductie-resultaten zijn gepubliceerd. Het vol-
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gende gedeelte beschrijft de postmortem bevindingen van een grotere groep pati-
enten die TAVI ondergaan hebben. Obductie werd uitgevoerd in 17 patiënten, 3 
kleppen werden verwijderd bij patiënten tijdens open-hart chirurgie. Van de 17 
patiënten stierven er 9 binnen 7 dagen na TAVI, 4 tussen dag 7 en 30, en 4 gedu-
rende de periode tussen 30 dagen en 30 maanden. Drie kleppen werden chirurgisch 
verwijderd na 108 – 336 dagen. 
 Een frequent voorkomende bevinding was een niet-ronde vorm van de klep, 
zonder tekenen van verhoogde klepdegeneratie. Hetzelfde werd gezien in dramati-
sche klep- en stentdeformatie in een aantal casussen na borstcompressies gedu-
rende reanimatie. Paravalvulaire defecten werden veel gevonden, maar correspon-
deerden niet met paravalvulaire regurgitatie tijdens het leven. Hetzelfde gold voor 
niet-ronde stentconfiguraties of milde onjuiste uitlijning van de klep-stents. Ingroei 
van fibreus weefsel werd laat na TAVI gevonden, variërend van mild tot uitgebreid, 
maar leidde maar bij één geval tot interferentie met mobiliteit van een klepblad. 
Een andere interessante vondst was schade aan het geleidingssysteem door directe 
traumatische schade (zoals door de stent of gecalcificeerd klepweefsel) en ischemi-
sche schade (zoals door compressie door de stent van kleine septale arteriën die 
het geleidingssysteem van bloed voorzien). Hoofdstamobstructie vond plaats in 
twee patiënten, beiden met een korte afstand tussen het ostium van de linker coro-
nairarterie en de annulus, ondanks de normale grootte van de sinus van Valsalva. In 
een patiënt met een kleine en ernstig gecalcificeerde annulus ontstond een annulai-
re scheur waardoor communicatie tussen de linkerventrikel uitstroomtraject en het 
atrium ontstond, met daarbij ruptuur van het anterieure blad van de mitralisklep - 
dit leidde dit hemodynamische collaps en dood. In een derde van de patiënten was 
myocardiale amyloïdose te zien, wat bijgedragen kan hebben aan progressief hart-
falen, leidend tot de dood bij 3 patiënten (na 40-493 dagen na TAVI). 
 Langere follow-up van de kleppen kan nodig zijn om de klinische relevantie van 
ingroei van fibreus weefsel te bepalen, dat mogelijk kan leiden tot klepdegeneratie 
op de langere termijn. In dat geval kan een herhaalde transcatheter procedure 
(klep-in-klep) het probleem verhelpen. 
Hoofdstuk 3 
In dit hoofdstuk worden vasculaire complicaties, nierschade en pacemakerimplan-
tatie besproken, gevolgd door een discussie gefocust op de meeste ernstige compli-
catie na TAVI: het cerebrovasculaire accident. 
 Hoewel initiële analyses van de PARTNER-trials meer vroege neurologische 
complicaties toonde voor TAVI vergeleken met chirurgie, trokken de incidenties 
steeds verder naar elkaar toe. Methoden om het aantal CVA’s na TAVI te verminde-
ren zijn welkom, maar de beschermingsdevices zijn naar mijn mening niet geschikt 
hiervoor en zullen het probleem niet oplossen. Dit is gebaseerd op vroege bevin-
dingen over deze devices: er ontstonden even veel of zelfs meer ischemische laesies 
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bij het gebruik van deze devices, wat impliceert dat het plaatsen van deze devices 
met risico’s gepaard gaat. Daarbij vindt maar 50% van de CVA’s intraprocedureel 
plaats. Er zijn meer veelbelovende methoden die de prevalentie van neurologische 
complicaties kunnen verminderen: (1) verminderen van de grootte van de implan-
tatiesystemenkunnen kan deze systemen minder traumatisch maken en (2) in pati-
enten met atriumfibrilleren kan simultane afsluiting van het linker hartoor de pre-
valentie verminderen. De subgroep van TAVI-patiënten met atriumfibrilleren heeft 
niet alleen een hoog risico op trombo-embolieën, maar ook op ernstige bloedingen 
(als orale anticoagulantia worden voorgeschreven). Afsluiting van het linker hart-
oor is even effectief voor wat betreft het voorkomen van CVA, maar kent een signi-
ficant lager risico op bloeding. 
 Hierna worden de bevindingen van de postmortem studie bediscussieerd. Le-
vensduur van de transcatheterkleppen is een belangrijke kwestie. Zelfs als er klep-
degeneratie is na verloop van tijd (wat valt te verwachten), maakt de mogelijkheid 
tot een herhaalde transcatheter klep-in-klep procedure het mogelijk jongere en 
laag-risicopatiënten te behandelen met deze nieuwe techniek. Schade aan het myo-
card kan acuut ontstaan door verplaatsing van de native klepbladen, waardoor het 
ostium van een coronair geobstrueerd kan worden. Daarbij, in het geval van coro-
narialijden, kunnen zelfs niet-significante stenoses leiden tot ischemie bij langere 
periodes van hypotensie (bijvoorbeeld tijdens snelle pacing). Het is nog steeds on-
derwerp van discussie of niet-significante stenoses gerevasculariseerd zouden 
moeten worden vóór TAVI. 
 Een apicaal sluitingsdevice die een volledig percutane apicale toegang mogelijk 
maakt (mogelijk zelfs onder lokale anesthesie) wordt mogelijk minder belangrijk 
voor TAVI in de toekomst, gezien de huidige technische ontwikkelingen waardoor 
een transfemorale benadering in steeds meer patiënten mogelijk wordt (waarbij 
het meest recente implantatiesysteem maar een 14 French sheath nodig heeft). Er 
blijven echter patiënten waarbij transfemorale toegang niet mogelijk is wegens 
perifeer vaatlijden. Daarbij zijn er ook devices in ontwikkeling voor percutane mi-
tralisklepvervanging, wat kan leiden tot opleving van de transapicale toegangsweg. 
Door deze toegangsweg minder invasief te maken, kunnen uitkomsten mogelijk 
verbeterd worden in de toekomst. 
 De laatste paragraaf van dit hoofdstuk focust op de aankomende klinische ont-
wikkelingen van de TAVI-procedure: naar mijn mening is het combineren van pro-
cedures (bijvoorbeeld percutane coronaire revascularisatie, afsluiting van het lin-
ker hartoor en TAVI) patiënt- en kostenvriendelijk en zou dat vaker moeten plaats-
vinden. Ik hoop dat ad-hoc TAVI in de toekomst werkelijkheid wordt. Ad-hoc TAVI 
met gecombineerde procedures beschrijven mijn visie op hoe TAVI in de toekomst 
uitgevoerd zou moeten worden. 
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